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Abstract 
Inter-ethnic differences in drug metabolism have been reported in numerous studies, 
which compared Asian or Chinese to Caucasian populations. A discontinuous 
distribution of the iV-oxidation oftrimethylamine (TMA) to trimethylamine A^ -oxide 
(TMAO) has been described in population samples from Britain (Caucasians), Jordan, 
Ecuador, N e w Guinea and Thailand which appear to be due to the genetic 
polymorphism ofthe flavin-containing monooxygenase (FMO). In view ofthe lack of 
published data for Chinese populations, this study was conducted to determine the 
distribution of T M A A^ -oxidation in the Chinese population in Hong Kong. Other 
factors that may affect TMAA^-oxidation in man have also been examined in this study. 
Chinese male subjects (n = 270) were recruited. Urine samples were collected for the 
determination of T M A and T M A O by gas chromatography. The percentage of total 
T M A excreted as T M A O (calculated as T M A ) in urine was determined. The frequency 
distribution for the percentage of total T M A excreted as T M A O showed a similar 
pattern to previous studies in British Caucasian populations. Most subjects excreted 
more than 90 % o f T M A as T M A O but the distribution was skewed with an asymmetric 
tail extending toward lower values. Totally, the combined result from 24-hour and spot 
urine samples showed seven subjects (3 % ) who excreted 80-90 % o f T M A as T M A O 
and another two subjects (1 % ) who excreted 74 % and 75 % of T M A as T M A O 
respectively. 
Data were also analyzed to investigate the effect of age and diets on the ability o f T M A 
A^ -oxidation. From the results obtained, regarding the activity of F M O on T M A N-
oxidation, there seems to be no direct relationship (correlation) to the age of male 
volunteers, although a U-shaped relationship for the % T M A oxidation at different ages 
was obtained. The difference in the amounts o f T M A and T M A O excreted within the 
urine collection periods might be due to other factors including dietary changes. The 
dietary study showed that seafood is the major source of T M A and T M A O , such that 
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intake of seafood (as high intakes of T M A and T M A O ) stimulated the initial F M O 
activity and led to higher percentage T M A A^ -oxidation. It also produced persisting 
effects on the rate o f T M A O excretion and the percentage o f T M A excreted as T M A O 
in urine. 
Effects of diseases and medications were also reported in this study. Damage ofthe 
liver (cirrhosis) impaired the liver function and reduced the liver F M O activity, which 
led to a lower percentage value o f T M A iV-oxidation. Therefore, cautious prescription 
is needed for the drugs that are metabolized by F M O in these patients. The effects of 
two different drugs, atorvastatin and hydroxychloroquine (HCQ), were also studied. 
Atorvastatin had no effect on the percentage of T M A 7V-oxidation. For H C Q , the mean 
values for percentage TMAA^-oxidation were similar in patients treated with it to those 
who were not. However, three patients treated with H C Q showed reduced percentage 
of T M A 7V"0xidati0n (78 - 88 %). The effects of other drugs on T M A 7V~oxidation 
should be systematically studied. 
In conclusion, at least 1 % ofthe Chinese population studied may have mild deficiency 
in TMAA^-oxidation, which may represent impairment due to genetic or other factors. 
There appears to be no clear relationship between age and the degree of T M A N-
oxidation but dietary factors such as a high intake o f T M A and T M A O for example in 
seafood appear to influence the F M O activity as demonstrated by T M A TV-oxidation. 
Cirrhosis of the liver is associated with reduced T M A A/-oxidation, but diabetes, 
hyperlipidaemia and hypertension had no significant effect, and treatment with the 
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1.1 Overview of pharmacogenetics 
Pharmacogenetics is the study of individual variations in both the rate and the 
pattern of drug metabolism in human. It involves the investigation of a large 
number of rare genetic traits that show unusual drug reactions because of the 
effects of impaired enzymatic activity. The concept of pharmacogenetics was 
first described by Sir Archibald Garrod who recognized the causal 
relationships between the inheritance of defective genes and deficiencies of 
specific enzymes that produced several “inborn errors of metabolism" 
including albinism (Garrod, 1909). According to the marked differences of 
genetic constitution in each human body, it was suggested that individual 
differences in drug and chemical reactions could be predicted (Garrod, 1931). 
The concepts were further developed and recognized as a special field of study 
called pharmacogenetics by Motulsky (1957) and Vogel (1959). Therefore, 
studies in pharmacogenetics nowadays include a combination of 
pharmacology, pharmacy, biochemistry, genetics, and molecular biology in 
order to identify and study unusual responses with drugs or xenobiotics due to 
genetic variations. 
A number of enzymes and/or their enzyme-related systems including 
esterases, transferases, dehydrogenases, cytochrome P-450s, and other 
oxidoreductases, showed genetic variations in their response to drugs and 
xenobiotics Enzyme variants showed abnormal activities when compared to 
the normal enzymes There are two examples of esterases exhibiting genetic 
variations The first example is butyrylcholinesterase (cholinesterase), which 
hydrolyzes succinylcholine to form succinylmonocholine and choline 
Succinylcholine was commonly used in the 1950's as a muscle relaxant to 
produce a prompt and complete paralysis, followed by rapid recovery, with 
little toxic side efTects However, the muscle paralysis for people with 
atypical butyrylcholinesterase could last for hours rather than the usual 2 lo 6 
minutes. These patients were maintained on mechanical ventilators because 
they were unable to breathe This atypical butyrylcholinesterase variant which 
failed to hydrolyze succinylcholine was observed by Kalow (1956), and 
Kalow and Staron (1957) also showed that atypical butyrylcholinesterase was 
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a heritable trait. Population studies showed that the frequency of the atypical 
allele of butyrylcholinesterase varied from 0.017 in European populations 
(0.017 is equal to 1 out of3500 people with the homozygous atypical allele) to 
0.076 for Jews in Iran (Whittaker, 1986). The second example is human 
serum paraoxonase, which catalyzes the hydrolysis of paraoxon and a number 
of other organophosphates, aromatic carboxylic acid esters and carbamates. 
Paraoxon is the metabolite of parathion (an insecticide) by cytochrome P450, 
in which the sulphur atom in parathion is replaced by oxygen atom. It has two 
genetically determined polymorphic forms. Type A has lower paraoxonase 
activity, while type B has much higher paraoxonase activity. These two types 
of isozyme showed a bimodal distribution in the first Caucasian 
pharmacogenetic study (Krisch, 1968). However, unimodal distributions of 
serum paraoxonase levels were found in some African and Oriental 
populations including Nigerians and Chinese (Playfer et al., 1976). These 
results also showed that the paraoxonase activity was different in various 
populations, resulting from genetic polymorphism. For transferases, a 
polymorphism in A^ -acetyltransferase in man was discovered when isoniazid 
was used in tuberculous patients, in whom 68 % of patients excreted the 
administered dose in urine in a conjugated microbiologically inactive form, 
and the remaining patients excreted it in an un-conjugated form (Bonicke and 
Reif, 1953). This genetic variation was confirmed as a bimodal distribution 
(slow metabolizers and rapid metabolizers) by Biehl in 1957. The slow 
acetylators of certain therapeutic drugs (isoniazid, sulphamethazine, etc.) were 
more susceptible to adverse effects than the rapid acetylators because less 
drugs were cleared from the body and thus remained in the body at higher 
concentrations. Although the distribution of A^ -acetyltransferase activity was 
bimodal in the previously described study, Sunahara et al. (1963) showed a 
trimodal distribution of A^ -acetyltransferase in a Japanese population, in whom 
three genotypes (slow homozygotes, intermediate heterozygotes, and rapid 
homozygotes) were recognized by microbiological assay. Moreover, the 
'rapid' acetylators represented over 90 % in Eskimo and Japanese populations, 
but some Arab, Indian, and European populations showed 70 % of slow 
acetylators. Those results showed that genetic variations occurred with 
different frequencies in various populations (Price Evans, 1992). Another 
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typical transferase is human glutathione ^ -transferase (GST). It contains six 
different isozyme groups named GST1, GST2, GST3, GST4, GST5, and 
GST6. GSTs catalyze the conjugation reaction between reduced glutathione 
(GSH) and electrophiles, including some mutagens and carcinogens such as 
ethylene oxide, styrene oxide and benzo[a]pyrene, etc. (Seidegard et al., 1985; 
Warholm et al., 1981) All the isozymes are the products from at least three 
genetic loci: GST1, GST2, and GST3 (Board, 1981; Laisney et al, 1984; 
Strange et al., 1984). The products from the GST1 loci show genetic 
polymorphism and four phenotypes: G S T 1 1, GST1 2-1, G S T 1 2, and G S T 1 
0; are exhibited. Moreover, the phenotype GST1 0 indicates a deficiency 
allele at the GST1 locus and it had been found to be the most common type in 
various populations, while the other three phenotypes occur in different 
frequencies in different ethnic groups. This indicated that individuals who are 
at high risk of cancer are presented in various ethnic groups but in different 
proportions. Alcohol dehydrogenase and aldehyde dehydrogenase are two 
well-known dehydrogenases. Alcohol dehydrogenase (ADH) participates as 
the principal oxidative pathway for ethanol metabolism in mammals. It 
catalyzes the oxidation of primary and secondary alcohols to aldehydes and 
ketones. A D H contains at least five different gene loci (ADHi to ADH5) 
which code for human A D H which is formed arising from a random dimeric 
association from eight different type of subunits. A D H is also divided into 
three classes (I, n, and III), while atypical A D H arises from the ADH2 locus 
(Von Wartburg and Schurch, 1968) and contains a variant B2 subunit instead 
ofthe usual Bi subunit. Moreover, this atypical enzyme has a higher catalytic 
activity than the normal enzyme at pH 8.8. The occurrence of the atypical 
A D H enzyme was around 5-10 % in British Caucasian populations (Edwards 
and Price Evans, 1967; Smith et al., 1971 & 1972), but it occurred in up to 85 
% in Asian populations (Borson and Li, 1986; Fong et al., 1989; Fukui and 
Wakasugi, 1972; Harada et a!., 1980; Ikuta et al., 1988; Ogata and Mizohata, 
1973; Stamatoyannopoulos et al, 1975; Teng et al., 1979). Aldehyde 
dehydrogenase (ALDH) acts to detoxify acetaldehyde and other aldehydes in 
human organs and tissues. Two major isozymes, A L D H 1 and A L D H 2 occur 
in humans and A L D H 2 shows genetic polymorphism. Pervious studies 
described that A L D H 2 showed a lack of activity in Asian populations 
4 
(Agarwal et al., 1981; Goedde et al., 1979; Fong et al., 1989; Goedde and 
Agarwal, 1981; Harada et al., 1980), instead of Caucasian populations 
(Goedde and Agarwal, 1981; Harada, et al., 1978). The reason was a point 
mutation that occurred at the 14^ position from the C-terminus, where the 
glutamic acid was substituted in the deficient isozyme by lysine (Hempel et 
al., 1984 & 1985). The cytochrome P-450s (CYPs) are a family of enzymes 
that can be found throughout the animal and plant kingdoms. It contains many 
gene families: I，II, III, IV, VI, VII, XI, XVII, XIX, XXI, XXVI, LI, LE, 
LXXI, XI, XII, adrenodoxin，and adrenodoxin reductase. The P-450s within 
the P-450I, P-450n, and P-450in gene families metabolize drugs and 
carcinogens. Some of the CYPs exhibit genetic polymorphism resulting in 
altered drug metabolism. One of the best examples is the hydroxylation by 
CYP2D6. This is a major metabolic pathway for debrisoquine and some other 
cardiovascular agents, including the beta-blockers propranolol and metoprolol 
and antiarrhythmics such as flecainide. In Caucasian populations about 5-10% 
of subjects were found to be poor metabolizers through this isozyme, whereas 
Oriental populations had almost no poor metabolizers (Lou, 1990). However, 
in Chinese the extensive metabolizers appeared to have a lower average 
metabolic capacity for debrisoquine hydroxylation than Caucasians. Poor 
metabolizers are homozygous for an autosomal recessive gene but the reduced 
metabolism in extensive metabolizers appears to be due to two other 
polymorphisms in CYP2D6, C/Tigg and G/C4268, which are highly associated 
and the Tigg and C4268 alleles are more common in Chinese. Moreover, a 
major metabolic pathway for propranolol metabolism was 4-hydroxylation by 
CYP2D6 and the Tigg allele was associated with reduced metabolism of 
propranolol, particularly S-propranolol (Lai et al., 1995). However, the area 
under the curves were lower for propranolol and higher for 4-
hydroxypropranolol in Chinese compared to white American subjects in an 
earlier study (Zhou et al., 1989), although the beta-blocking and hypotensive 
effects of propranolol were greater in the Chinese subjects. It appeared that 
there was a larger interindividual variation in propranolol disposition in 
Chinese than in white subjects so it should be used more judiciously in 
Chinese patients (Lai et al., 1995) which is usual in clinical practice. Other 
cytochrome P450 enzymes showing genetic polymorphisms with different 
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frequencies in Asians and Caucasians include impaired S-mephenytoin 
hydroxylation (CYP2C19), which was more common in Chinese and Japanese 
than Caucasians. Nifedipine is also subject to extensive first-pass oxidative 
metabolism through CYP3A4. Plasma levels of nifedipine were found to be 
higher in Asians than in Caucasians (Ahsan et al., 1991) and this may result in 
a greater hypotensive effect. CYP3A4 is an important metabolic pathway for 
other calcium channel blockers and many other drugs, so ethnic differences in 
these might be expected although no polymorphism in the gene for CYP3A4 
has been discovered yet to account for these differences. Other important 
enzymes, for example, flavin-containing monooxygenase also exhibit genetic 
polymorphism in several populations as demonstrated by the measurement of 
the extent of TV-oxidation of trimethylamine (TMA) to trimethylamine 7V-oxide 
(TMAO) in man (Al-Waiz et al., 1987b; Hadidi et al, 1995; Mitchell et al., 
1997; Thithapandha, 1997; Zhang et aL, 1996a). F M O includes five isoforms: 
FM01, FM02, FM03, FM04, and FM05. Deficiency o f F M O activity leads 
to impaired 7V>oxidation of some drugs, e.g. nicotine, chlorpromazine, etc. 
(Ayesh and Smith, 1992). The sufferer of homozygous deficiency ofFM03 
has a fishy-body smell, due to the severe impairment of A^ -oxidation of T M A 
to T M A O . This genetic disease is called 'fish-odour syndrome'. 
Most pharmacogenetic conditions have been seen from the responses to drugs 
in a large number of patients under standard dosages. Some patients appeared 
to be undertreated, while others required smaller doses to obtaining the normal 
pharmacological responses. Therefore, this wide range of individual 
responses to a standard dose was reproducible for each individual, and would 
be expected for an inherited trait (La Du, 1992). Moreover, many 
pharmacogenetic studies related to drug responses are carried out now because 
unusual drug responses may be harmful to patients. On the other hand, certain 
compounds or their metabolites in foods, e.g. T M A , may also be affected by 
or interact with the metabolic polymorphism, due to the structural similarities, 
inhibitory effects, etc. Carsin et al. (1956) found that treatment with drugs, 
such as primaquine, caused haemolysis in primaquine sensitive red blood 
cells, due the deficiency of glucose-6-phosphate dehydrogenase (G6PD). 
Moreover, a similar G6PD defect was suspected to be the cause of erythrocyte 
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haemolysis in some people in the Mediterranean area after the ingestion of 
Fava beans (Favism), because an unknown compound or its metabolites from 
the beans acted like primaquine in these susceptible individuals. 
The wide variation of genetically controlled individual also has a profound 
effect on pharmacokinetics and the rates of drug removal from the body. 
Therefore, the primary objective of pharmacogenetic study has been to learn 
the genetic basis of adverse drug reactions which arise as the consequence of 
abnormal or defective proteins, for example enzymes, binding proteins 
(Alexanderson and Borga, 1972), and receptors. It is particularly related to 
genetic mutations of defective or isozymic forms of drug metabolism enzymes 
produced by allelic genes, which may be dominant or recessive. 
Both animal models and human may be utilized in pharmacogenetic study. 
Animal models may be useful to elucidate the molecular basis and 
physiological mechanisms of human disease. Also, the pharmacological and 
toxicological consequences of the trait can be determined by animal studies in 
responders of differing, known genotypes and phenotypes under carefully 
controlled conditions that are unattainable in human studies. There are many 
animal models used in the study of genetic polymorphism, which include 
genetic polymorphisms of the Ah receptor, of P450 variants of CYP2D6 
(debrisoquine hydroxylation polymorphism) and of CYP2B1 in rats; genetic 
polymorphism of A^ -acetyltransferase in rats, mice, hamsters and rabbits; 
thiopurine methyltransferase polymorphism in mice; and the occurrence of 
sensitivity and resistance to bleomycin in mice (Weber, 1997). In human 
studies, general population surveys by phenotyping have often been utilized. 
Affected individuals are first identified in the population study, their genetic 
traits can then be detected in the family members and classified as 
homozygous (affected or unaffected) or heterozygous phenotypes. The 
phenotyping would often make use of the ratio of drug/xenobiotic to 
dmg/xenobiotic metabolites in body fluids. One good example is the current 
phenotyping study of flavin-containing monooxygenase (FMO) activity using 
trimethylamine (TMA) TV-oxidation. Other methods such as autopsy liver 
samples were used for the glutathione S-transferase polymorphism (Harada et 
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al., 1987) and in atypical alcohol dehydrogenase investigation (Von Wartburg 
and Schurch, 1968). Percentage of inhibition of dibucaine was also used for 
phenotyping of typical and atypical butyrylcholinesterases in human, this 
percentage was called dibucaine number (Kalow and Genest, 1957). 
Differences in response to salt were also utilized in the examination of 
paraoxonase activity (Smolen et al., 1982). Molecular biology techniques 
have also been used increasingly to identify the variants of enzymes, which 
participate in the metabolic polymorphisms (Skoda et al., 1988; McGurie et 
al., 1989). 
1.2 Clinical importance of nitrogen oxidations 
Many common drugs and xenobiotics, e.g. imipramine, 7V,7V-dimethylaniline, 
trimethylamine, tamoxifen, nicotine, pargyline, A^ -ethyl-7V-methylaniline, 
guanethidine contain nitrogen in their chemical structures. Nitrogen is one of 
the three major elements, the other two being carbon and hydrogen, commonly 
present in xenobiotics. The most common nitrogen containing groups in drugs 
are primary amines, secondary amines, tertiary alkylamines or arylamines 
(Cholerton and Smith, 1991). Flavin-containing monooxygenases, 
cytochrome P-450s and several other enzymes are involved in the oxidation 
(7V"Oxidation) of the nitrogen containing groups in there drugs converting them 
into the corresponding A^ -oxides. One good example is the conversion of 
trimethylamine (TMA) to its A^ -oxide, trimethylamine 7V-oxide (TMAO). The 
formation of a dative bond where the nitrogen atom donates two electrons to 
form a single saturated bond with oxygen atom, and the reduced basicity are 
two characteristics for this 7V-oxide (Fig. 1.1). Figure 1.2 also summarizes 
some typical examples of drugs and their metabolites, which undergo nitrogen 
oxidations by F M O . 
Generally speaking, the metabolites of xenobiotics by nitrogen oxidation 
should be ‘less toxic’ to the body. Therefore, A^ -oxidation may be classified as 
a detoxification process in most instances. 
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CH3 CH3 
H 3 C - N : • H 3 C — N ~ ~ • 〇 
C H 3 C H 3 
Fig. 1.1 The conversion of trimethylamine (TMA) to trimethylamine TV-
oxide (TMAO) 
1.3 Characteristics of trimethylamine (TMA) 
Trimethylamine (TMA) is a volatile tertiary amine (boiling point, 3°C), which 
has malodorous characteristics (Fig. 1.1). It has a low olfactory threshold (< 1 
ppm) and resembles the smell of rotting fish. T M A occurs normally in its 
odourless 7V-oxide form, trimethylamine iV-oxide (TMAO) (Fig. 1.1), in fish, 
especially in marine fish (Dyer, 1962; Shewan, 1951). In mammals, T M A is 
additionally derived from the degradation by gut bacteria of common dietary 
components, such as choline, carnitine, and lecithin, which are present in 
major foodstuffs including eggs, liver, and soybean (Cholerton and Smith, 
1991) (Fig. 1.3). Most of the T M A absorbed in man is metabolized by N-
oxidation to T M A O by a flavin-containing monooxygenase (FMO) and the 
T M A O is excreted in the urine along with a small amount of T M A (Al-Waiz 
etal., 1987a). 
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Fig. 1.2 Some drugs which undergo nitrogen oxidations by F M O 
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Fig. 1.3 Precursors of trimethvlamine in foods 
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T M A O is formed by the oxidation of T M A together with the formation of a 
dative bond in between the nitrogen and oxygen atoms. It is an odourless and 
non-volatile compound (melting point, 255-257 °C). With respect to the 
absorption and disposition of T M A O , 50 % of a dose of this A^-oxide appeared 
to be well absorbed and excreted unchanged when given to normal volunteers. 
The remainder was reduced, by gut floral enzymes to trimethylamine, which 
was absorbed and subsequently metabolized to the iV-oxide (Al-Waiz et al., 
1987b). This process has been named as "metabolic retroversion". 
T M A and/or its precursors are present in many major foodstuffs (Table 1.1). 
A major source of T M A is from the marine fishes and the amount of T M A O 
can comprise up to 0.5 % of the body weight in marine fish. On the other 
hand, beef and other meats do not contain T M A and its oxide, but with 
significant amounts of carnitine and choline in red and white meats 
respectively. Carnitine and choline are two major precursors ofTMA. 
1.4 Genetic polymorphism of trimethylamine A^-oxidation 
Normally, T M A undergoes A^ -oxidation to T M A O in the body by flavin-
containing monooxygenase. The odorless and less volatile A^-oxide is excreted 
mainly in the urine but also to a slight extent in the sweat and the breath. 
Normal individuals excrete around 50 mg of total trimethylamine each day, 
and most of the trimethylamine (> 90 % ) is excreted as its TV-oxide. The 
extent of A^ -oxidation of T M A to T M A O in man had been described in 
pervious studies in various ethnic groups and showed a polymorphic 
distribution (Al-Waiz et al., 1987b; Hadidi et al, 1995; Mitchell et al., 1997; 
Thithapandha, 1997; Zhang et al., 1996a). Although the majority of subjects 
excreted more than 90% of the total T M A in the form o f T M A O , the incidence 
of T M A A^ -oxidation deficiency varied from at least 1% (British Caucasian) to 
probably 11% QS[ew Guinean) within the studied ethnic groups. 
Deficiency of T M A 7V-oxidation showed various degrees of severity. The 
most severe form is an inherited metabolic disorder. In affected individuals, 





























































































































































































in the free T M A form rather than in its oxide form. Subjects suffering from 
this condition have an odour of rotting fish and this may result in severe 
psychosocial problems for the individual. According to these characteristics, 
this genetic disorder is called ‘Trimethylaminuria' or 'Fish-odour Syndrome’ 
(Humbert etal., 1970; Ayesh et al., 1993; Mitchell, 1996). It appears that the 
A^ -oxidation of T M A is controlled by a single autosomal diallelic locus in 
which one allele induces extensive T M A TV-oxidation while the uncommon 
variant allele results in impairment of this process. Individuals with the fish-
odour syndrome are homozygous for the allele determining impaired 
metabolism. Since this syndrome is primarily a genetic defect, it is called 
‘primary trimethylaminuria' as distinguishable from other forms of 
trimethylaminuria, caused by external non-genetic factors. 
The rotting-fish smell from sufferers of ‘trimethylaminuria‘ was detected at 
different ages. Some sufferers were confirmed by their parents to have a fishy 
smell just after birth (Lee, et aL, 1976; Pike et al., 1988)，while others were 
only recognized at puberty (Danks et al., 1976; Marks et al., 1976). The 
condition became more severe during menstruation in female sufferers (Ayesh 
et cd., 1993). The intensity of the smell may vary in different subjects, often 
enhanced through exercise and emotion when sweating is increased. 
Moreover, the serious body smell caused social difficulties at school in the 
childhood years, and led to aggressive behavior and educational disadvantages 
for the sufferers (Todd, 1979). 
Moderate impairment of metabolism occurred when the subject has one 
variant allele for T M A A^ -oxidation. These heterozygous unaffected subjects 
appeared normal under usual dietary conditions, but they developed a fish-
odour under heavy exposure to T M A , including an oral challenge with T M A , 
due to saturation of T M A iV-oxidation ability (Ayesh et al., 1993). The 
subjects suffering with this abnormality were 'secondary trimethylaminurics,, 
who had this underlying genetic abnormality but required additional 
environmental factors to manifest the phenotype. Factors that contribute to 
different extents to the impairment of T M A 7V-oxidation in man include 
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precursor overload (e.g. choline), liver and renal disease, hormonal effects, 
inhibitors of the T M A oxidizing system, vaginal disease, and drug treatments. 
The significance of these factors are discussed further in Chapters 4 and 5. 
The factors affecting this syndrome and the severity or their manifestations are 
summarized in Table 1.2. 
1.5 Enzyme systems mediating trimethylamine 7V-oxidation 
Many drugs and xenobiotics are substrates for both the flavin-containing 
monooxygenases (FMOs) and the cytochrome P-450-dependent 
monooxygenases, F M O s are responsible for the TV-oxidation of trimethylamine 
(TMA) to its 7V"Oxide (TMAO) (Ziegler, 1980). The flavin-containing 
monooxygenase (FMO) was first purified in 1972 from pig liver (Ziegler and 
Mitchell, 1972). The enzyme was difficult to sequence because of the blocked 
N-terminus and other technical difficulties. With the recent development of 
molecular biology techniques, isozymes of F M O were identified and cloned 
(Gasser et al., 1990; Lawton et aL, 1990). According to the amino acid 
sequences, five distinct F M O isozymes were identified and classified as: 
FM01, FM02, FM03, FM04, and FM05, all of which have different 
functions in the human body (Gasser, 1996). 
F M 0 1 is found mainly in human kidney and not the liver. Therefore, it should 
not be involved in the genetic disease of trimethylaminuria. On the other 
hand, Northern blot analysis showed F M 0 1 m R N A was abundant in the fetal 
stage, indicating that F M 0 1 is required for regulation in body growth. F M 0 2 
is abundant in human lung, and also found in liver and in kidney. In rabbit 
lung, F M 0 2 is predominantly localized in the nonciliated bronchiolar 
epithelial (Clara) cell, in addition to ciliated, endothelial, type I, and type II 
cells and in the tracheal lining layer (Overby et al., 1992). It is almost 85 % 
similar to the human FM02. It catalyzes 7V^ -oxygenation of alkylamines to 
oximes but has no effect on the primary arylamines (Poulsen et al., 1986). 
F M 0 3 was first isolated from human liver by Lomri et al. in 1992 and it was 
15 
Table 1.2 Factors affecting Tish-odour svndrome’ 
、T ^ ^ , Genetic 。 . 
No. Factors Syndrome effect Severity 
Homozygous for the 
1 allele determining 1° Trimethylaminuria Yes Most severe 
impaired metabolism 
TT p , Moderate, 
Heterozygous for the depends on 
2 allele determining 2° Trimethylaminuria Yes other non 
impaired metabolism genetic factor 
Moderate, 
3 Precursor overload 2° Trimethylaminuria N o associated with 
factor (2) 
4 Liver disease 2° Trimethylaminuria N o 二 ^ factor^ !^ )^  
5 Renal disease 2° Trimethylaminuria N o 二 ^ Ta(^ v^^ (3) 
6 Vaginal disease 2° Trimethylaminuria N o Moderate 
， T^ . ‘ ,o rp . 丄 1 . . 、T Mild, associated 
7 Dietary enzyme 2° Trimethylaminuria N o • / ^  .^. 
inhibitors  
Enhance the 
8 Hormonal effect N/A N o syndrome 
caused by 
factors (1) & (2) 
Enhance the 
9 Drug effect N/A N o syndrome 
caused by 
factors (1) & (2) 
16 
found to exhibit distinct stereoselectivity for oxygenation of cimetidine and S-
nicotine (Cashman et al., 1995). Moreover, F M 0 3 is abundant in human liver 
and now it is generally believed to be the major isoform for the A^ -oxidation of 
T M A (Cashman, 1995). Another minor isoform of F M O is FM04. It is 
present in human brain and liver. However, its function and substrate 
specificity remain unknown. F M 0 5 also occurs in human liver (Phillips et al., 
1995). It is inactive with methimazole, a general substrate, but highly active 
with n-octylamine. The relative abundance of different isoforms of F M O in 
the organs of the human body is summarized in Table 1.3. 
The enzyme responsible for T M A TV-oxidation was initially thought to be 
F M 0 1 (Dolphin et al., 1991), but subsequent shown that only a small amount 
o f F M 0 1 was found in human liver (Burnett et al., 1994; Cashman et al., 
1993; Lomri et al., 1992; Sadeque, et al., 1992; Wrighton et al, 1993). Liver 
F M 0 3 was generally thought to be the major enzyme for T M A TV-oxidation in 
humans (Cashman, 1995; Zhang et al., 1996a). It appears that the isoform 
F M 0 3 of the flavin-containing monooxygenases (FMOs) is the major enzyme 
involved in the A^ -oxidation of trimethylamine into trimethylamine 7V-oxide. 
Moreover, its gene is located on human chromosome lq (Shephard et al., 
1993), and contains one non-coding and eight coding exons (Dolphin et al., 
1997a). A C ^ T missense mutation, corresponding to nucleotide 551 in the 
cDNA, was identified in exon 4 of both F M 0 3 alleles of the primary 
trimethylaminurics (homozygous affected subjects). The mutation changes a 
C C C proline triplet at codon 153 to a C T C leucine triplet (Prol53^Leul53). 
The parents (heterozygous unaffected subjects) were heterozygous for triplets 
at this position, while the non-trimethylaminurics (homozygous unaffected 
subjects) were homozygous for a C C C triplet at the same position (Dolphin et 
a/.，1997b). It was possible that the proline to leucine substitution in codon 
153 caused protein tertiary structural changes that result in abnormal protein 
folding and an inactive human F M 0 3 (Treacy et al., 1998). This finding may 
be useful to provide a new picture of the genetic polymorphism in T M A N-
oxidation. 
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Table 1.3 Relative abundance of different isoforms of F M O in the organs of 
the human body 
Isoform Organ Abundance* 
F M 0 1 Kidney +++ 
Liver ++ 
F M 0 2 
Kidney ++ 
F M 0 3 Liver +++++ 
Brain + 
F M 0 4 
Liver ++ 
F M 0 5 Liver ++++ 
* + sign represent the relative abundance of the corresponding isozyme in the organ 
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1.6 Aims and objectives 
Inter-ethnic differences in drug metabolizing enzymes have been reported in 
numerous studies involving Asian and Chinese populations, which constitute 
one of the largest ethnic groups in the world (Kiniron et al., 1996; Lee at el, 
1988; Lou, 1990; Lou et al., 1987; Sowunmi et al., 1995; Wang et al., 1997; 
Xie et al., 1996; Zhou et al., 1989), and these may be caused by genetic 
variations. For example, the metabolism of debrisoquine showed an incidence 
of poor metabolizers of about 3-10% in various European populations, but less 
than 1% in Chinese (Lee at el., 1988; Lou, 1990; Lou et al., 1987). However, 
the distribution of T M A A^ -oxidation had been studied in a number of ethnic 
groups (British Caucasian, Ecuadorian, Jordanian, and Thai), but not in the 
Chinese population. Therefore, the first objective in this study was to 
determine the distribution of this metabolic trait in the Chinese population in 
Hong Kong. Moreover, the effect of age on the ability for T M A TV-oxidation 
in Chinese male subjects was also examined as the second objective. The 
third objective in this study was to determine the effects of diet on total T M A 
and T M A O excretion in Chinese male subjects. Since T M A and T M A O , and 
their precursors are present in many types of foods, including fish, beef, etc., 
the effects of diet and the dietary habits in southern Chinese was examined to 
see if there was any significant difference in T M A and T M A O excretion in 
Chinese compared to other ethnic groups. The fourth objective of the study 
was to examine if any disease factors affected T M A and T M A O excretion in 
certain patient categories including liver disease, renal disease, diabetes, and 
patients treated with lipid-lowering drugs. 
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2.1 Introduction 
Sensitive and specific analytical techniques have been used in many metabolic 
studies to characterize drugs and their metabolites. Many of these techniques 
have been described in detail for drug and metabolite characterizations, 
including colorimetry, ultra-violet/visible (UV/VIS) spectrophotometry, infra-
red (IR) spectrophotometry, mass spectrometry (MS), nuclear magnetic 
resonance QSfMR) spectroscopy, high-performance liquid chromatography 
(HPLC), gas chromatography (GC), etc. These methods are useful in the 
determination of different drugs and their metabolites, according to their 
physical and chemical properties. Quantitation and characterization of drugs 
and their metabolites by colorimetry and UV/VIS spectrophotometry have 
been popular in the past, and methods based on formation of coloured or U V 
absorbable complexes with chemical reagents are available for many 
metabolic reactions, e.g. the determination of the A^-oxides of N’N-
dialkylanilines by Ziegler and Pettit (1964). However, the colorimetric and 
UV/VIS spectrophotometric methods are limited in their use because of their 
low sensitivity and lack of specificity (Damani, 1985). JR spectrophotometry 
is also used for drug characterization, but it has its own limitations for drug 
and metabolite analysis including low sensitivity, and the difficulties in 
spectrum interpretation. Therefore, JK spectrophotometry is generally used in 
qualitative drug identifications. N M R spectroscopy and M S are two modern 
techniques in qualitative and quantitative dmg and metabolite analyses. N M R 
phenomenon occurs when nuclei, e.g. ^H, ^^C, in the molecule under 
investigation aligned with an applied field are induced to absorb energy and 
change their spin orientation with respect to the applied field. On the other 
hand, M S is a result of the alternation of path, by the application of magnetic 
field, of the pieces of ions in which breakdown from the molecule under 
investigation after the electron bombardment or chemical ionization process. 
Both techniques can produce specific and sensitive results in dmg and 
metabolite analysis including T M A and T M A O determinations (Abeling et al., 
1995; DaCosta et aL, 1990; Hirama et aL, 1993; Tjoa and Fennessey, 1991). 
However, these two sophisticated techniques require expensive equipment and 
high maintenance cost, and therefore are not common in many laboratories. 
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Chromatography, including G C and HPLC, is a very popular technique in 
drug and metabolite determinations in modern laboratories, so it needs to be 
described clearly. The primary characteristic of chromatography is that two 
mutually immiscible phases are brought into contact; one phase is stationary 
and the other mobile. When a sample is introduced into the column, it will be 
carried by the mobile phase. The sample components interact with the mobile 
phase and stationary phase to different extents. These repeated interactions of 
the sample components with the stationary and mobile phases cause 
separation. Since the interactions are different for different components, the 
least interactingy^ retarded component will leave the column first and the most 
interacting one will stay in the column for the longer period. The separated 
components, in the form ofbands, are directed to the end of the column, where 
they can be detected by some type of detector or collected by suitable 
apparatus. The most important part in chromatography is the column. It 
provides flexibility for different analysis. Different stationary/mobile phases, 
length of column, temperature, pressure, additives, and the combinations of 
these factors can further extend the range and depth of the component 
separations. This versatility has helped chromatography to become the most 
favoured separation technique in research and in product development. 
Moreover, the use of different types of detectors, e.g. thermal-conductivity 
detector (TCD), flame-ionization detector (FDD), electron-capture detector 
(ECD), nitrogen-phosphorus detector (WD), mass spectroscopic detector 
(MSD), etc; also helps the researcher for specific analysis of the sample 
components. The mobile phase can be a gas or a liquid, but the stationary 
phase can be only a liquid or a solid. Table 2.1 describes the general 
classification of the present chromatographic techniques. Although it can be 
subdivided into many variations, the two most common chromatographic 
techniques in analysis are gas-liquid chromatography (GLC) and liquid-liquid 
chromatography (LLC). Liquid-liquid chromatography performed under high 
pressure increased the performance of separation. It is now defined as high-
performance liquid chromatography (HPLC). Before the invention of gas 
chromatography, drug analysis and metabolism studies used column, paper or 

































































































































their metabolites. One major problem was the detection limits and 
sensitivities with the above techniques. Drugs and their metabolites in sample 
fluids are mostly found in very low levels, and this led to the development of 
more sophisticated techniques for the analysis. In the last twenty years, the 
rapid development of gas chromatography (GC) and high-performance liquid 
chromatography (HPLC) helped to solve most of the above problems. 
H P L C is one of the most common techniques for drug and metabolite analysis, 
especially when the molecules are large, non-volatile, or thermally unstable. 
Moreover, H P L C can separate macromolecules, ionic species, labile and 
polymeric materials, etc, and the components can be quantitative recovered. 
Many drug characterizations are based on the H P L C techniques rather than the 
old colormetric techniques (Szepesi, 1990). Separation and quantitative 
determination of many sulphur-containing compounds have also been 
performed by HPLC. One good example is the separation and quantitative 
determination of sulindac sulphide and its oxygenated metabolites by reversed 
phase H P L C (Swanson and Boppana, 1981). Another example is the 
characterizations of sulphinpyrazone and its sulphoxide and sulphone 
metabolites by M<-Bondapak C18 HPLC column (Renwick et al., 1982). 
Although H P L C is effective for drug and metabolite characterizations, gas 
chromatography (GC), especially gas-liquid chromatography (GLC), is still 
very useful for the separation of thermally stable and volatile organic and 
inorganic compounds. It is especially effective because the flow restriction in 
a G C column is lower than in the H P L C column. Therefore, the time of 
analysis can be greatly reduced when a suitable column is chosen. Other 
advantages, including the simple operating principle and the possibility of 
coupling it to a mass spectrometer or an infrared spectrophotometer, result in 
G L C still being used in many laboratories. 
G L C is commonly used in the determination of amines and their derivatives in 
metabolic studies. Many methods have been developed throughout the last 
decade. The samples can be analyzed after the addition of alkali, either by 

































































































organic solvent before analysis. Marzo et al. (1990) described the direct 
injection method for aliphatic amines by G C using a flame-ionization detector 
(FK)) and thermionic specific detector (TSD). Lundh and Akesson (1993) 
used derivatization with isobutyl chloroformate to determine primary and 
secondary low-molecular-mass aliphatic amines in urine. Pfundstein et al. 
(1991) also employed gas chromatography and chemiluminescence detection 
with a modified thermal energy analyzer for primary and secondary amines. 
Some researchers also employed the headspace method for amine analysis. A 
recent published article by Kataoka (1996) also reviewed the methods of 
amine determination by gas chromatography, and this research group also 
utilized derivatization and flame photometric detection for primary and 
secondary amine determinations (Kataoka et al., 1992 & 1993). On the other 
hand, Krzymien and Elias (1990) used the headspace G C method to determine 
fish freshness by T M A measurement. Zhang et al. (1992) also used a very 
sensitive and simple headspace method to determine amines in urine samples. 
This sensitive headspace assay with suitable modifications was applied in this 
research study. Details are described in the following sections. 
In this research study, the headspace G L C method was employed to determine 
the amounts of trimethylamine (TMA) in urine samples and the reduced 
trimethylamine TV-oxide (TMAO) as T M A after treatment with titanium (III) 
chloride. 
2.2 Materials 
Gas-liquid chromatography was performed on an H P 5890 Series II 
chromatograph together with an H P 3396 Series II Integrator (Hewlett-
Packard Company, Avondale, U.S.A.), equipped with a flame-ionization 
detector and a glass made packed column (2.4 m x 4 mm). The stationary 
phase, Carbowax 20 M , was purchased from Chrompack International B.V. 
(Middelburg, The Netherlands). Graphitized carbon support (60-80 mesh) 
Carbopack B and the 5 ml gas-tight G C syringe with sample lock was 
purchased from Supelco (Bellefonte, PA, U.S.A.). Potassium hydroxide for 
the stationary phase preparation and for sample treatment, hydrochloric acid 
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for the preparation of standard solutions, and chloroform for dissolving G C 
stationary phase, were purchased from B D H Chemical Limited (Poole, Dorset, 
U.K.). Trimethylamine hydrochloride salt (primary standard), isopropylamine 
(99 % ) solution (internal standard), and dimethyl-dichlorosilane solution 
(silanizing agent) were obtained from Sigma Chemical Company (St. Louis, 
M O , U.S.A.). High-purity nitrogen (>99.99 % ) (carrier gas), compressed air 
and hydrogen (for FK) ignition) were supplied from Chun W a n Industrial Gas 
Company (Hong Kong, China). 5 ml glass sample vials, rubber stoppers, 
aluminium caps, and the capping/decapping apparatus for urine sample 
holding were purchased from Wheaton Company (Millville, NJ, U.S.A.). The 
water bath for urine samples heating was bought from Cole-Parmer 
International (Vernon Hills, JL, U.S.A.). 
2.3 Methods 
2.3.1 Preparation of stock solutions 
0.01 M hydrochloric acid solution for the preparation of stock 
solutions was prepared from the 0.1 mol 1"^  hydrochloric acid ampoule 
by suitable dilution with deionized-distilled water. In the preparation 
of trimethylamine standard solution, trimethylamine stock solution at 1 
mg ml—i was firstly prepared from the trimethylamine hydrochloride 
salt in 0.01 M hydrochloric acid solution. For convenience, 
trimethylamine intermediate solution at 50 i^g ml'^  was also prepared 
from the stock solution in 0.01 M hydrochloric acid solution. The 
solutions were kept in a refrigerator at 4。C. In the preparation of 
isopropylamine internal standard solution, isopropylamine stock 
solution at 2 % (v/v) was prepared from the isopropylamine (99 % 
w/w) solution in 0.01 M hydrochloric acid solution and also kept at 
4。C. 
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2.3.2 Preparation of GLC glass column 
An empty pre-coiled G C glass column (2.4 m x 4 m m ) was first 
cleaned with chromic acid followed by rinsing three times with 
deionized water and methanol. Then, it was cleaned with silanizing 
agent—dimethyldichlorosilane followed by rinses with deionized water 
and methanol. It was dried in an oven at 60 °C. 
To coat the stationary phase on solid support, a suitable amount of 
Carbowax 20 M and potassium hydroxide were weighed in a round 
bottom flask. This was then dissolved in chloroform. Solid support 
(Carbopack B, 60-80 mesh) was added to the chloroform solution and 
the mixture was allowed to stand overnight at room temperature. This 
resulting slurry was then evaporated to dryness on a rotary film 
evaporator (J. Bibby, Stone, U.K.) at 70 °C. To ensure complete 
dryness for the coated support, it was further heated in an oven at 100 
°C for 1 hour. The resulting solid support was 4 % Carbowax 
20 M/0.8 % potassium hydroxide on Carbopack B (60-80 mesh). 
The Carbowax 20 M coated Carbopack B solid support was packed 
into the empty glass column with the aid of a vacuum pump (J. Bibby, 
Stone, U.K.) with gentle vibration by hand. Silanized glass wool was 
plugged into one end of the column where the vacuum was applied. 
The other end of the column was plugged with a small funnel for ease 
of material transfer. When the column was fiilly packed with solid 
support, the funnel was removed and silanized glass wool was plugged 
into this end. The column was then installed into the gas 
chromatograph. To remove volatile impurities and to ensure tight 
packing, the column was conditioned overnight below the 
recommended maximum operating temperature (220 °C) of the 
stationary phase with the carrier gas (high purity nitrogen) flowing. 
After overnight conditioning, the column was inspected by eye for any 
loose packing. It was then detached from the gas chromatograph, the 
glass wool plug at the inlet was removed and an extra amount of solid 
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support was then added to ensure tight packing. When the glass wool 
was re-plugged into the column, it was then reinstalled into the gas 
chromatograph. The above conditioning procedures were repeated until 
no loose packing was observed. 
2.3.3 Optimizing GLC conditions for the separation of trimethylarnine 
The optimum G L C operating conditions for trimethylamine analysis 
were: 
Injection port temperature: 170 °C 
FID detector temperature: 200 °C 
Oven temperature: 70 °C 
Carrier gas (nitrogen) flow rate: 32 mi min"' 
Glass column dimension: 2.4 m x 4 m m 
Solid packing: 4 % Carbowax 20 M/ 
on potassium hydroxide on 
Carbopack B (60-80 mesh) 
Hydrogen flow rate for FlD 55 ml min"' 
Compressed air t1ovv rate for FID 250 ml min'' 
Auxiliary nitrogen flow rate for FID 60 ml min'' 
2.3.4 Sample prctreatment for (;L(，ana/ysis 
To analyze irimelhylamine (TMA) and trimethylamine A,-oxide 
( T M A O ) in urine, 0 2 % (v/v) isopropylamine was prepared as the 
internal standard by 1 in 10 dilution from 2 % (v7v) isopropylamine 
stock solution with 0 01 M hvdrochloric acid The workinu 0 2 % 
‘ w 
(v/v) isopropylamine internal standard solution was used within one 
week 
For the determination o f T M A in urine. 2 ml of urine sample was put 
into a 5 ml glass vial immersed in an ice baih 80 ul 0 2 % (v/v) 
isopropylamine internal standard solution was then added into the vial 
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1.2 g potassium hydroxide powder was added to bring the pH > 10 to 
convert the T M A in urine to its free base form. The vial was stoppered 
with a rubber stopper immediately and capped with an aluminium cap. 
The sample-in-vial was then shaken with a vortex to ensure all K O H 
powders were dissolved. It was put back into the ice bath until the 
temperature had appropriately dropped. The sample-in-vial was then 
put into a water bath at 90 °C for 20 minutes. After 20 minutes, 2 ml 
of headspace gas in glass vial was removed by a gas tight syringe. It 
was held in the syringe by closing the sample lock in the syringe. The 
syringe was then inserted into the G C injection port and the sample 
lock was released. The gas was then totally injected into the column 
and the integration was started at the same time. 
T M A O was not analyzed by G L C directly, it was first reduced to T M A 
by titanium (III) chloride. Then, the total amount of T M A (free 
T M A + T M A from the reduction o f T M A O ) was detected by GLC, and 
the T M A O (as T M A ) amount was determined by subtraction the value 
of total amount of T M A (i.e. T M A + T M A O (as TMA)). For the 
determination of total T M A , 1 ml of urine sample was put into a plastic 
sample vial together with 200 ^ 1 of 15 % (w/v) titanium (III) chloride 
(reducing agent). The vial was capped and left at room temperature for 
30 minutes. Then, 4 ml of deionized water was added into the vial and 
it was shaken well. After this, 2 ml of this solution was added into the 
glass vial in ice bath and the same procedure was followed as in T M A 
determination. 
The peak area ratio for T M A to isopropylamine and the amount of 
T M A in the sample solution were determined and calculated by 
suitable mathematical calculations (Section 2.3.8). If the peak area 
ratio exceeded the range of the calibration curve, the urine sample was 
diluted with deionized water appropriately and it was re-analyzed. 
Section 2.3.8 describes the calculations o f T M A (free T M A ) and T M A 
+ T M A O (as T M A ) (total T M A ) in urine sample. 
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2.3.5 Construction of calibration curve 
To construct the calibration curve, trimethylamine (TMA) intermediate 
solution (50 i^g ml"^) was used to prepare a series of T M A standard 
solutions. This T M A intermediate solution was kept for 3 months at 
4°C. 
T M A standard solutions (0.1 ^ g ml"^  to 10 ^ g ml"^) were prepared by 
dilution with 0.01 M hydrochloric acid. Nine different concentrations 
of T M A standard solutions were employed to construct this calibration 
curve: 0.1, 0.2, 0.3, 0.5, 0.8, 2.0, 5.0, 8.0 ,10.0 ^ ig mr\ All points 
were performed in duplicate and on three consecutive days, and 
therefore six sets of data were obtained. 
2.3.6 Determination of the amount of titanium (III) chloride required for 
trimethylamine N-oxide reduction 
The amount of titanium (III) chloride required for trimethylamine TV-
oxide (TMAO) reduction to trimethylamine (TMA) in the urine 
samples was determined. Two urine samples were chosen for 
determination in the same day. One sample contained high amounts of 
T M A and T M A O and another sample contained little amounts o f T M A 
and T M A O . 
2.3.7 Intra- and inter-assay variations 
Intra-assay variation was calculated by multiple analysis of the same 
urine sample in a single assay, while inter-assay variation was 
determined by repeated analysis of aliquots of the same urine samples 
over three months. 
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2.3.8 Equations used in the determinations of free TMA, total TMA, and 
percentage TMA excreted as TMAO 
Equations 2.1 & 2.2 describe the mathematical determinations of free 
T M A and total T M A in urine sample. 
Amount of T M A in urine sample (free T M A ) (mg)= 
Concentration of T M A (free T M A ) in urine sample for G C analysis 
([igAnl) X (dilution factor) x Volume of urine excreted (ml) + 1000 
Note: (dilution factor) = 1 when sample dilution is not required. For 
1 in 10 dilution, (dilution factor) = 10，etc. 
(Equation 2.1) 
Amount o f T M A + T M A O (as T M A ) 
in urine sample (total T M A ) (mg)= 
Concentration o f T M A + T M A O (as T M A ) (total T M A ) in urine sample 
for G C analysis (|igAnl) x (dilution factor) x 5.2 x Volume of urine 
excreted (ml) + 1000 
Note: (dilution factor) = 1 when sample dilution is not required. For 
1 in 10 dilution, (dilution factor) = 10, etc. 
(Equation 2.2) 
An equation to determine the percentage of T M A excreted as T M A O 
in urine was also developed, in order to classify the volunteers and 
patients as to whether they suffered from trimethylaminuria (fish-odour 
syndrome) or an intermediate deficiency in T M A A^ -oxidation. 
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Percentage T M A excreted as T M A O = 
Total T M A - Free T M A 
X 1 0 0 % 
Total T M A 
(Equation 2.3) 
2.4 Results 
2.4.1 GLC chromatogram 
The typical G L C chromatogram is shown in Fig. 2.2. Peaks of 
trimethylamine (TMA) and the internal standard, isopropylamine, were 
well separated and without any interference from unwanted peaks. 
The retention times for T M A and isopropylamine were 5.2 mins and 
7.9 mins. respectively. The total run time for one injection was less 
than 10 minutes. The conditions are listed at Section 2.3.3. 
2.4.2 Construction of calibration curve 
The calibration curve was constructed combining all these sets of data 
as described in Section 2.3.5 (Fig. 2.3). 
2.4.3 Determination of the amount of titanium (III) chloride required for 
trimethylamine N-oxide reduction 
One sample contained high amounts of T M A and T M A O and the final 
amount o f T M A + T M A from reduced T M A O was located near the high 
end of the calibration curve. On the contrary, another sample 
contained little amounts of T M A and T M A O and the final amount of 
T M A + T M A from reduced T M A O was located at the low end of the 
calibration curve (Fig. 2.4). 
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Fig. 2.4 Determination the amount of titanium fIII) chloride for the 
reduction of urine T M A O to TMA： ---•— low T M A + T M A O 
sample. ~•一 high T M A + T M A O sample (each points represents 
the mean and standard deviation of three separate determinations) 
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2.4.4 Intra- and inter-assay variations 
Intra-assay variation determination produced a coefficient of variation 
ofl.3 % for T M A (0.93 土 0.01 ^ g/ml, mean 土 s.d.，n = 5) and 3.7 % 
for T M A + T M A O (as T M A ) (98.19 士 3.64, mean 土 s.d., n = 5) (Fig. 
2.5). Inter-assay variation resulted in a coefficient of variation of 3.9 
% for T M A (0.43 土 0.02 pgAnl, mean 土 s.d., n = 6) and 2.4 % for 
T M A + T M A O (as T M A ) (7.83 士 0.19 ^ g/ml, mean 士 s.d., n = 6) (Fig. 
2.6). 
2.5 Discussion 
In this study, headspace sampling was employed rather than the traditional 
liquid injection technique. The reason was the low boiling points for T M A 
(b.p. 3 °C) and the internal standard-isopropylamine (b.p. 32 °C), and that the 
partition coefficient allowed sufficient amounts of them into the gaseous 
phase. Therefore, time-consuming extraction of T M A from the urine sample 
could be avoided Most of the impurities with high-boiling points in urine 
were not vaporized and the headspace gas in the glass vial mainly consisted of 
vaporized T M A and isopropylamine. 
The calibration curve ranging from 0.1-10 ^ g ml'^  was established with good 
linearity. It was non-linear beyond 10 ^g ml'V Therefore, only the linear 
range from 0.1 \ig/m\ to 10 |ig/ml of T M A was utilized to create one 
calibration curve because samples with large amounts of T M A and T M A O 
would be subjected to suitable dilution. Moreover, a flame-ionization detector 
was used in G L C rather than the other specific detectors, e.g. nitrogen-
phosphorus detector, because it was well suited for the range of T M A 
detection. 
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The optimal amount of titanium (III) chloride for T M A O reduction was 
determined. Fig. 2.4 described the effect of different amounts of titanium (III) 
chloride on the results of T M A + T M A O in the samples. Two samples were 
employed. For the low T A M + T M A O sample, it showed no significant 
difference of T M A + T M A O amounts at different concentration of titanium 
(III) chloride added (50-400 ^g ml"^ ). Although the determined 
T M A + T M A O amounts varied slightly at the sample with high T M A + T M A O 
amounts, it was still reasonable to use 200 )ig ml'^  titanium (III) chloride 
because this amount showed an optimal result for T M A + T M A O . 
The exact values of intra- and inter-assay variations are described in Figures 
2.5 and 2.6. Coefficients of variations were smaller than 4 % . Therefore, it 
was possible to analyze urine samples within three months after the collection, 
without significant change in T M A and T M A O amounts. Therefore, a rapid 
and sensitive analytical method by headspace gas chromatograph was 
developed for the analysis of urinary T M A and T M A O . It was used for the 
experiments described in the other chapters. 
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3.1 Introduction 
The genetic polymorphism of trimethylamine (TMA) #-oxidation, as 
described in Chapter 1，can be divided to three categories. The first category 
is the normal group, which constitutes the majority of the population. These 
people excrete more than 90 % of T M A as T M A O in urine and the flavin-
containing monooxygenase (FMO) is fully functional. The second category 
includes people who excreted 60-90 % of T M A as T M A O in urine. This 
condition is known as 'secondary trimethylaminuria', which can result from 
genetic or non-genetic factors (Chapter 1). The third category is the 
homozygous inherited metabolic disorder, in which most of the T M A is 
excreted through urine, sweat, breath and other secretions in the free T M A 
form rather than in its oxide form. This genetic disorder is termed 'primary 
trimethylaminuria' or 'fish-odour syndrome，(Ayesh et al,, 1993; Humbert et 
al., 1970; Mitchell, 1996)，and the percentage of T M A as T M A O in the urine 
is less than 60 % . 
The distribution of this genetic polymorphism was first investigated in a 
British Caucasian population (n = 169) by Al-Waiz et al. (1987). In this 
study, no primary trimethylaminuric was found except one subject (1 % ) who 
showed moderate impairment in T M A TV-oxidation. The distribution was 
skewed with a tail extending towards the lower values in the negative direction 
from the median. The polymorphic distribution of T M A 7V-oxidation has been 
studied in some other ethnic groups. Zhang et al. (1996a) also extended the 
study (n 二 421) in a British Caucasian population and they found a similar 
result as in the initial study (1 % ) with impairment in T M A A/-oxidation. 
Hadidi et al. (1995) carried out a study in a Jordanian population. They found 
that about 8 of 82 subjects (10 % ) had impaired ability in T M A A^ -oxidation. 
Mitchell et al. (1997) studied the discontinuous A^ -oxidation oftrimethylamine 
among Jordanian (n =116，1/3 day urine collection), Ecuadorian (n = 80, spot 
urine) and N e w Guinean (n = 100，spot urine) populations based on a 1/3 day 
urine collection or a spot urine study. It was found that the proportion of 
subjects with a relative deficiency iniV-oxidation were 1.7 % in Jordanian, 3.8 
% in Ecuadorian, and 11.0 % in N e w Guinean. 
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Recently, a study has been carried in Thailand (Thithapandha, 1997). 
Although the study recruited 5 probands with clinical trimethylaminuria for 
urine analysis, the regular population study (n = 103) only showed around 4 % 
subjects had impaired T M A A^ -oxidation (with the aid of T M A load test only). 
The other non-genetic factors such as age, diet, and disease, affecting 
secondary trimethylaminuria will be discussed in Chapters 4 & 5. 
3.2 Experimental protocols 
Chinese male subjects (age range from 18 to 64 years) were recruited for the 
study. All the subjects were fully informed in writing of the study 
requirements and their written consents were obtained. The subjects 
completed a questionnaire (Appendices A.1 and A.2), providing details of 
fluid/food consumption over the periods of urine collection, with details of any 
medication taken within the previous week. None of the volunteers reported 
having any organic disease. Two concurrent protocols: 1) whole day urine 
collections; and 2) spot urine collections, were carried out simultaneously. 
The whole day urine collection protocol was used in most of the previous 
studies (Al-Waiz et al., 1987b; Hadidi et al, 1995; Mitchell et al., 1997; 
Thithapandha, 1997; Zhang et al., 1996a), but a spot urine collection protocol 
was used in only one recent study (Mitchell et al., 1997). Also, no comparison 
was done before between these two protocols. In this study, these two 
protocols were used simultaneously and compared together, in order to 
determine the differences and similarities for these two protocols. 
3.2.1 Whole day urine collections 
The 24 hour urine samples were collected in four contiguous periods: 
1) midnight (bedtime) to 7:00 a.m. (before breakfast); 
2) 7:00 a.m. (after breakfast) to 1:00 p.m. (before lunch); 
3) 1:00 p.m. (after lunch) to 7:00 p.m. (before dinner); and 
4) 7:00 p.m. (after dinner) to midnight (before bedtime). 
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Urine from each individual period was collected in a plastic bottle 
already containing hydrochloric acid (5 ml; 3 M). The corrected 
volume (volume of acid was subtracted) of urine excreted in each 
period was measured and a 50 ml aliquot was stored at -20 °C until 
analysis of T M A and T M A O . 
3.2.2 Spot urine collections 
For the spot urine collection, as a more convenient and straightforward 
protocol than 24-hr urine collection for primary trimethylaminuric 
screening, the volunteer was asked to provide only one urine sample 
after waking (7:00 a.m.) and before taking any food or drink. The 
urine sample was collected in a plastic bottle already containing 
hydrochloric acid (5 ml; 3 M ) and a 50 ml aliquot was stored at -20。C 
for analysis o f T M A and T M A O . 
3.3 Results 
3.3.1 Whole day urine collections 
Results were obtained for 159 Chinese male subjects aged 28.0 士 9.6 
years (mean 士 s.d.) of whom 13 subjects were regular smokers (5 to 25 
cigarettes per day) and the results are shown in Table 3.1. Results 
obtained in British male subjects from a previous study (Zhang et al., 
1996a) were included for comparison. The amount o f T M A O excreted 
(79.4 土 118.6 mg in Chinese, 53.7 mg in British, calculated as T M A ) 
was much higher than that of free T M A (1.4 士 1.5 mg in Chinese, 1.6 
mg in British). The large variation of T M A O (calculated as T M A ) 
excreted in both Chinese (3.5-947.0 mg) and British (4.0-965.7) might 
be caused by the variations of dietary intake among the subjects. Both 




















































































































































































































































































































































































































































Figure 3.1 showed the frequency distribution of the percentage of total 
T M A excreted as T M A O in urine for the subjects under whole day 
urine collection. The majority of subjects excreted more than 90 % of 
T M A as T M A O in urine with mean and median values of 96.7 % and 
96.6 % respectively. The distribution was skewed (skewness -3.61, 
Table 3.1) with an asymmetric tail extending toward lower values. 
Moreover, kurtosis gave a value of 17.33 (Table 3.1), which indicated 
it was a relatively peaked distribution when compared with the normal 
distribution. The pattern of the frequency distribution was very similar 
to that in the British male subjects, as described by skewness (-1.6) and 
kurtosis (3.3) in Table 3.1. In the present study of Chinese male 
subjects, five subjects (3 % ) excreted 80-90 % of T M A as T M A O and 
another two subjects (1 % ) excreted 74 % and 75 % o f T M A as T M A O 
respectively. 
3.3.2 Spot urine collections 
Results were obtained for 111 Chinese male subjects aged 38.0 士 12.3 
years (mean 士 s.d.) of whom 23 subjects were regular smokers (2 to 30 
cigarettes per day) and these are shown in the third column of Table 
3.2. The last column of combined data will be described in Section 
3.3.3. Figure 3.2 showed the frequency distribution of the percentage 
of total T M A excreted as T M A O in urine for the subjects in spot urine 
samples. The results were similar to those obtained in the whole day 
collection, the majority of subjects excreted more than 90 % of T M A 
as T M A O in urine with mean and median values of 96.7 % and 97.3 % 
respectively. The distribution was skewed (skewness -1.15) with an 
asymmetric tail extending toward lower values. Although kurtosis 
gave a value of 1.04 because of missing extreme outliners (< 70 % of 
T M A excreted as TMAO), a relatively peaked distribution was still 
presented when compared with the normal distribution. Two subjects 
(1 % ) excreted 80-90 % of T M A as T M A O but no subject excreted 
less than 80 % o f T M A as T M A O respectively. 
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Fig. 3.1 Frequency distribution histogram for the percentage total trimethylamine 
(TMA) excreted as trimethvlamine A/"-oxide (TMAO) in urine during 24 h 
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Fig. 3.2 Frequency distribution histogram for the percentage total trimethylamine 
(TMA) excreted as trimethylamine iV-oxide (TMAO) in urine by spot urine 
test in a Chinese population (n = 111). 
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3.3.3 Comparison between whole day urine collections and spot urine 
collections protocols 
Statistical tests were performed to compare the whole day urine 
collections and spot urine collections protocols. In spot urine 
protocols, as samples were collected in the morning, the percentage 
values o f T M A excreted as T M A O from all age groups were compared 
to the values obtained at Period 1 (12:00 a.m. to 7:00 a.m.) in the 
whole day urine collection, and also to the whole day combined 
percentage values. In this comparison, Kruskal-Wallis One Way 
Analysis of Variance on Ranks was performed since the distributions 
were skewed and not in a Gaussian form (normality test failed, p < 
0.001). It was found that the p value was greater than 0.05, so the 
differences in the median values among the treatment groups were not 
great enough to exclude the possibility that the difference was due to 
random sampling variability. The unpaired t-test or Mann-Whitney U-
test also produced no statistical difference (p > 0.05) when performed 
to compare the morning session (Period 1) of the 24 hr collection 
protocol and the spot urine data within all age groups combined. 
Therefore, it appeared to make no statistical difference to choose spot 
urine collections or whole day urine collections for the investigation of 
the general distribution of T M A iV-oxidation. It was considered that 
this statistical insignificance permitted us to combine data from the 
spot urine tests and data from whole day urine collections for the 
investigation of the general distribution of T M A #-oxidation, and the 
combined data are plotted in Figure 3.3. 
Figure 3.3 showed the frequency distribution of the percentage of total 
T M A excreted as T M A O in urine for the subjects in spot urine tests 
and in whole day urine collections (n = 270). The majority of subjects 
excreted more than 90 % of T M A as T M A O in urine with mean and 
median values of 96.7 % and 97.4 % respectively (Table 3.2). 
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Fig. 3.3 Frequency distribution histogram for the percentage total trimethylamine 
(TMA) excreted as trimethylamine A^ -oxide (TMAO) in urine in a Chinese 
population (n = 270). Data combined from whole day urine collection and 
spot urine test. 
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asymmetric tail extending toward lower values. Kurtosis also had a 
value of 18.70. Totally, the combined result had seven subjects (3 % ) 
who excreted 80-90 % of T M A as T M A O and another two subjects (1 
% ) who excreted 74 % and 75 % o f T M A as T M A O respectively. 
3.3.4 Comparison between smokers and non-smokers 
Mann-Whitney Rank Sum Test had been performed for the smokers 
and non-smokers in this population study and it showed no statistical 
significance (p > 0.05) for the effect of smoking on the percentage 
TMAA^-oxidation (smoker: 96.4 ± 2.6 % , n = 36; non-smoker: 96.7± 
3.2%,n = 234; mean±s.d.). 
3.3.5 Comparison of the results obtained in four individual periods of whole 
day urine collections 
Data for individual periods of urine collection are described in Table 
3.3 and the curves are plotted in Figures 3.4 & 3.5. The data showed 
the highest amounts of T M A and T M A O excreted and the highest 
percentage value of T M A excreted as T M A O in Period 1. When 
compared to the corresponding data during the other three periods, 
significant results were obtained (p < 0.01, T M A ; p < 0.005, T M A O 
(calculated as TMA); p < 0.05, % T M A excreted as TMAO). Period 2 
showed the lowest values within the collection periods, and when 
compared the values to other three periods, significant results obtained 
for T M A Q? < 0.001) and T M A O (calculated as T M A ) (p < 0.005). 
When the % of T M A excreted as T M A O at Period 2 was compared to 






























































































































































































































































































































































































































































































































































































































































































































































































































In the present study, both whole day urine collections and spot urine test 
protocols were utilized concurrently. They were compared to determine the 
differences and similarities for these two protocols by statistical tests, as 
described in Section 3.3.3, on the results of percentage T M A A^ -oxidized to 
T M A O . In this comparison, Kruskal-Wallis One W a y Analysis of Variance 
on Ranks found that no statistical difference for these results and therefore 
there appeared to be no statistical difference to choose spot urine collections or 
whole day urine collections for the investigation of the general appearance of 
the distribution of T M A A^ -oxidation. Figure 3.3 showed the combined data 
from these two protocols for the primary trimethylaminuria investigation. The 
whole day, spot, and combined percentage values of T M A A^ -oxidized are 
already described in Table 3.2. Moreover, the whole day urine collection 
protocol in the present study had been modified from the original method. In 
previous studies (Al-Waiz et al., 1987; Hadidi et al., 1995; Thithapandha, 
1997; Zhang et al., 1996a), the excreted urine within the 24 hr period was 
collected in one large bottle. The matrix composite was then sampled at the 
end of this period. This was inconvenient for the volunteer to handle a large 
bottle and to keep it with them for a whole day. It also lost information 
regarding the amounts and rates of change of T M A and T M A O excretion, and 
the change of the percentage T M A excreted as T M A O during the collection 
period. Therefore, the current 24-hr urine collection was divided into four 
contiguous periods (see Section 3.2.1), and for each period the subject was 
provided with a smaller sized urine collection bottles. This made it possible 
for the volunteers to continue their normal duties and activities during the 
weekdays whilst making the urine collection. Furthermore, subdivided 
collection periods provided useful data on the effects of different types of diet 
and activities on the T M A and T M A O excretion. In Chapter 4, it is described 
more clearly about the changes of amounts/rates of T M A , T M A O , and 
percentage T M A excreted as T M A O in urine according to the changes of diet. 
Although spot urine tests could not display any persisting effect of dietary 
intake on T M A and T M A O excretion, it was not necessary to reject spot urine 
tests as another useful and convenient protocol for homozygous affected 
56 
subjects (primary trimethylaminurics) investigation. Moreover, a similar spot 
urine collection protocol had already been performed in Ecuadorian and N e w 
Guinean populations (Mitchell et al., 1996), and it was possible to develop 
interpretable polymorphic frequency distribution histograms for those 
populations. 
The amounts of T M A and T M A O excreted in the urine, and the percentage of 
T M A excreted as T M A O , were similar to those reported in previous studies 
(Al-Waiz et aL, 1987; Hadidi et aL, 1995; Zhang et al., 1996; Thithapandha, 
1997). Table 3.1 showed the amounts of T M A and T M A O , and the 
percentage o f T M A excreted as T M A O , in British male subjects (n = 221) in a 
recent study (Zhang et al.) 1996). The higher mean and median T M A O values 
in Chinese may be related to differences in dietary habits in southern China 
compared to Great Britain. For % T M A excreted as T M A O , it also showed 
similar results (96.0-96.7, mean; 96.3-97.6, median) in these British male 
subjects and in the Chinese male subjects under spot urine tests, 24 hr urine 
collections, and combined data. 
The frequency distribution for the degree of T M A 7V>oxidation obtained in this 
Chinese population was very similar to the distributions obtained in British 
Caucasian populations (Al-Waiz et al., 1987b; Zhang et al., 1996). None of 
the subjects in our study or in these two other studies were identified as 
primary trimethylaminurics under normal conditions. Intra-individual 
variation was not determined but a previous study showed a negligible effect 
(coefficient of variation < 1%) (Al-Waiz et al., 1987b). The majority of 
subjects in this and other studies excreted greater than 90% of the total T M A 
as T M A O in urine, and only few individuals (< 1%) excreted less than 80% 
T M A as T M A O in urine. In the British Caucasian population study (n 二 169) 
(Al-Waiz et al, 1987b), the subjects who had only slightly impaired ability in 
T M A A^ -oxidation under normal dietary conditions were identified as 
heterozygous carriers by a T M A load test. In the two subjects who excreted 
less than 80 % of T M A as T M A O , it may be reasonable to conclude that this 
moderate impairment of A^ -oxidation was consistent with carrier status for the 
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allele resulting in poor metabolism. However, previous studies of 
heterozygotes for the allele for impaired A^ -oxidation of T M A , who were 
identified as being the parents of subjects with the homozygous condition, 
showed that they often excreted more than 90% of T M A as T M A O under 
normal dietary conditions (Ayesh et al., 1993), so some heterozygotes could 
be missed by this screening test. Also, it is not certain whether subjects who 
excreted 80 to 90 % T M A as T M A O in urine are heterozygote carriers for the 
allele for poor metabolism. However, it is reasonable to assume that (without 
the T M A load test) subjects who excreted less than 80 % of T M A as T M A O 
in urine are the carriers of the allele for impaired T M A TV-oxidation (Mitchell 
etal., 1997), and a genetic deficiency in T M A A^ -oxidation presumably should 
occur in different populations. 
The second British Caucasian population study (n = 421) (Zhang et al., 1996) 
showed that the six subjects (1%) who excreted less than 80% of T M A as 
T M A O in urine were females. The over-representation by females in this 
study in Britain may be due to the interaction of metabolism and renal 
clearance, especially for compounds with high renal clearance (Jackson et al., 
1986). This was because of differences in the efficiency of secretory 
mechanisms or as a result of dietary habits as they affected urine pH and hence 
tubular reabsorption. Also, females who were suffering from bacterial 
vaginosis showed higher T M A levels in vaginal discharge than control 
females (Brand and Galask, 1986; Sardas et al, 1996), and it might affect the 
T M A level in urine samples taken from female volunteers. Also increased 
urinary T M A levels have been found in patients with cervical cancer as well 
as with vaginitis (Brewster and Schedewie, 1983). Although nicotine is a 
substrate for F M O , according to the information provided from the volunteers, 
apparently smoking did not alter the pattern of T M A iV-oxidation in this study 
{p>0.05) (Section3.3.4). 
U-shaped curves appeared for the results obtained for T M A and T M A O 
(calculated as T M A ) excretion and the percentage T M A excreted as T M A O in 
the four continuous periods (Figs. 3.4 & 3.5). Period 1 showed the highest 
values and period 2 and 3 produced relatively lower values than the first and 
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the last periods. The highest values for T M A and T M A O excretion at Period 
1 may be explained due to the longest duration for urine collection at this 
period than that at the other three periods. However, those values were 
increased again at Period 4. The high amounts of T M A and T M A O excreted 
in the urine during Periods 1 and 4 may be related to relatively high intake of 
food at the dinners before periods 1 and 4, since many foods contains T M A , 
T M A O and T M A precursors (e.g. choline, carnitine). The relative high 
percentages of T M A excreted as T M A O in urine at Periods 1 and 4, when 
compared to Period 2 and 3, may also be related to the high intakes of T M A , 
T M A O and T M A precursors. The study on the effects of foods will be 
described more clearly in Chapter 4. 
One subject who excreted less than 80% of T M A as T M A O in urine reported 
that he had eaten fried rice containing cauliflowers and sprouts at dinner just 
before starting the urine collection, and therefore as the percentage value of 
T M A excreted as T M A O in urine at Period 1 was lower than that at the 
subsequent periods, it may have been related to this food intake. Cauliflowers 
and sprouts are known to contain progoitrin, which is a potential inhibitor of 
T M A 7V-oxidation (Fenwick et al, 1982). The effect of progoitrin on T M A TV-
oxidation in man due to the consumption of these vegetables is still not clear 
(Fenwick et al., 1983). One previous study found Brussel sprouts and swede 
had no effect on the capacity to iV-oxidize T M A (Al-Waiz, 1988). Therefore, 
the effect of those vegetables on the low percentage T M A oxidation in this 
subject must be considered. These inhibitors may contribute to the reduction 
of the percentage of T M A excreted as T M A O to a certain extent, which might 
lead to a lower percentage value for T M A as T M A O in urine. 
Combined data for the percentage T M A #-oxidized (Fig. 3.3) were also 
transformed by logarithmic calculations to allow clearer visualization of 
whether there was the presence of a bimodal distribution. Figure 3.6 showed 
the frequency distribution of the logarithmic ratio of T M A excreted as T M A O 
in urine. In this logarithmic distribution histogram, no distinct bimodal 
distribution appeared. It is therefore more likely that the distribution is just 
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Fig. 3.6 Frequency distribution histogram for the logarithmic ratio of total 
trimethylamine (TMA) excreted as trimethylamine A^ -oxide (TMAO) in 
urine in a Chinese population (n — 270). Data combined from whole day 
urine collection and spot urine test. 
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One common problem for researchers is how to classify primary 
trimethylaminurics or secondary trimethylaminurics according to the 
percentage of T M A excreted as T M A O . The commonly accepted value to 
classify normal volunteers was > 90 % based on previous experience. 
However, there is some controversy about how to classify primary (frank) 
trimethylaminurics (homozygous affected subjects, severe impairment in 
T M A A^ -oxidation,) and secondary trimethylaminurics (including 
heterozygous unaffected subjects, moderate impairment in T M A A^ -oxidation). 
The borderline for separation of mildly affected cases (secondary 
trimethylaminuria) and the normal subjects (homozygous unaffected subjects) 
falls in the 80 to 90 % range, and the margin for categorizing of homozygous 
affected subjects was < 50 - 60 % . It should not be difficult to identify 
homozygous affected subjects because they should produce a fish-like 
unpleasant body odour. However, it is sometimes difficult to identify 
secondary trimethylaminurics because they may appear normal under normal 
dietary conditions. However, the % T M A conversion will be reduced if the 
intake of T M A and its precursors are high enough to saturate the liver F M O 
activity since the F M O activity is already impaired by genetic or other 
environmental or disease conditions (e.g. liver diseases). Although the T M A 
load test (Zhang et al., 1995) can be performed to identify these heterozygous 
subjects, it was not undertaken in this study, and it provides no background 
information about the effects of other environmental factors (e.g. diseases, 
drugs, and/or dietary effects). This study focused on the effects of these 
factors on T M A and T M A O excretion in a Chinese population. It will be 
discussed in more detail in the next chapter. 
Table 3.4 describes the results of impaired T M A #-oxidation in various 
populations. Initially, sufferers of Fish-odour syndrome were found in the 
Caucasian populations. However, recent studies also showed the existence of 
impaired T M A iV-oxidation in other ethnic groups including Southern Asians 
(Thithaoandha, 1997). In a Thai population, 5 sufferers were found clinically 
to have primary trimethylaminuria, but no sufferer was identified in a normal 

























































































































































































































































































































86 % ) of T M A as T M A O in urine, but some subjects (who originally had 
values > 90 % ) also showed impaired T M A A^ -oxidation after the T M A load 
test (> 80 % T M A excreted as TMAO). Zhang et al. (1995) also showed 
similar findings for the T M A load test in the obligate heterozygous unaffected 
subjects. This may mean that the margin (90 % T M A excreted as T M A O ) 
proposed by the researchers in the studies of British Caucasian populations is 
not a good and appropriate definition to classify homozygous unaffected 
subjects and heterozygous clinically unaffected subjects. Moreover, it is not 
clear whether all cases with a genetic cause have the same mutation and there 
are probably additional polymorphisms of the gene, which may have some 
effect. Therefore, the only way to resolve the problem is to examine a large 
population sample with phenotypes and genotypes. If a clear bimodal 
distribution is found this would suggest heterozygotes are showing reduced 
activity and an 'arbitrary' cut-off point can be made. It is more likely that the 
distribution is just skewed with a long tail due to environmental factors, 
diseases or one or more other polymorphisms. 
In conclusion, the statistical insignificance permitted us to combine data from 
these two protocols for the investigation of primary trimethylaminuria (Fig. 
3.3). Also, this study has shown that about 1 % of the Chinese population 
studied showed mild deficiency in T M A #-oxidation. To determine whether 
this represents a genetic variation or whether it is due to environmental or 
dietary factors will be the subject of further studies. Moreover, the results 
obtained in this study are very similar to the results obtained in the 
pharmacogenetic studies of another important liver enzyme: cytochrome P-
450 system, i.e. CYP2D6 activity in the hydroxylation of drugs. Initial studies 
distinguished two groups of subjects (poor metabolizers and extensive 
metabolizers) in Caucasian populations but not in Chinese. Therefore, it is 
reasonable to conclude that genetic polymorphism of enzymes may vary in 
different ethnic groups, and population studies should be carried out in various 
populations in order to obtain the fiill picture of the polymorphism. 
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4.1 Introduction 
The elderly represents a significant proportion of the population in many 
developed countries, e.g. in Hong Kong, European and North American 
countries. Elderly people are also one of the most medicated segments in 
those societies. In the USA, the elderly segment is the most medicated and 
accounts for 25 % of all prescription drugs dispensed (Christopher et al., 1979; 
Eckhardt, 1978). The cost of these prescribed drugs is more than $15 billion 
per year. Schmucker (1985) mentioned that this marked increase in drug 
treatments for the elderly was also linked to a greater incidence of adverse 
drug reactions in geriatric patients in comparison to younger subjects 
(Hurwitz, 1969; Schmucker etal., 1984). 
Although many studies reported that the effects of drugs are changed as a 
function of age, other studies did not show any significant effect of age on 
certain drug metabolism (summarized in Table 4.1). Moreover, studies also 
showed that drug metabolism by Phase II conjugation reactions was 
unchanged with normal aging (Greenblatt et al, 1982c), but the Phase I 
oxidation reactions declined with aging and resulted in the reduction of drug 
clearance in the elderly (Greenblatt etal., 1986; Montamat et al., 1989; Richey 
and Bender, 1977; Vestal, 1982). Phase I enzymes include both the 
cytochrome P450 enzymes and flavin-containing monooxygenase. Many 
investigations had been carried out on the effect of age on hepatic drug 
metabolizing enzymes in animal and in human. The results for animal liver 
drug metabolizing enzymes are listed in Table 4.2. On the other hand, the 
investigations of the effect of age of drug metabolizing enzymes in human 
liver had different results from the data obtained in animal studies. Most 
studies showed drug-metabolizing enzymes, e.g. cytochrome P450s are not 
affected by age. Wynne et al. (1988) studied the kinetics of the microsomal 
monooxygenase 7-ethoxycoumarin-O-de-ethylase in 17 human liver biopsy 
specimens, and no correlation was observed between age and microsomal 
protein recovery, maximal enzyme activity or apparent enzyme affinity. It 
was assumed that a fall in liver volume or blood flow should be the major 
cause for the decline in clearance of many oxidized drugs which occurs with 
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Table 4.1 Previous studies of the relation of age to the clearance of drugs cleared bv 
hepatic biotransformation (Data modified from Greenblatt et aL, 1982c) 
Drug or Metabolite Initial Pathwayof References 
b Biotransformation 
Evidence suggesting age-related reduction in clearance: 
0'Malley et al., 1971, Liddell et al., 1975, 
Antipyrine Oxidation Wood et al., 1979, Vestal et al., 1975, 
Greenblatt et al., 1982b  
Kanto et al., 1979, Macklon et al, 1979， 
Diazepam Oxidation Greenblatt et al., 1982a, Klotz et al., 1975， 
Ochs etal., 1981 
Chlordiazepoxide Oxidation Shader et al.，1977, Roberts et al., 1978 
^ ,^ , , . r ~ 7 7 Allen etal., 1980, Shader etal., 1981， 
Desmethyldiazepam 0>adatKm 馳 and Mtlller-Seydlitz, 1979 
DesaUcymurazepam Oxidation Greenblatt et al., 1981b  
Clobazam Oxidation Greenblatt et al., 1981a  
Alprazolam Oxidation Greenblatt etal., 1983 
Quinidine Oxidation "Ochs et al., 1978，Drayer et al., 1980 
Theophylline — Oxidation Jusko et al.，1979, AntaI et al., 1981  
D 1 1 TTT" VQSi2\etal, 1979, 
P r — o l o l Oxidation Castleden and George, 1979，Feely et al, 1981 
Nortriptyline Oxidation Dawlingg/^/., 1980 
Small or negligible age-related change in clearance: 
“ ~ ~ “ ^ Greenblatt et al., 1980， 
Oxazepam Glucuromdation ^ 騒 et al., 1976, Ochs et al., 1981 
T ^ , . , ,. Karuse/fl/., 1978, 
Lorazepam GlucuromdaUon 。 職 触 et al., 1979 
Temazepam Glucuronidation Divoll et al., 1981 
Warfarin Oxidation Sherpherd et al., 1977 
Lidocaine Oxidation Nation et al., 1977 
Nitrazepam Nitroreduction Castleden et al., 1977, Kangas et al., 1979 
^1 . “ Oxidation, Kantos etal., 1981 Fluitrazepam .备 , “ ，  mtroreduction  
Isoniazid Acetylation Farahg^Q/., 1977 
Ethanol Oxidation ^ e s t a l et al., 1977 
Metoprolol Oxidation Quartermangfa/.�1981 
Digitoxin Oxidation Donovang^ al., 1981 
Prazosin Oxidation Ruhinetal., 1981 
Data conflicting or not definitive: 
Meperidine Oxidation Metherg/ al., 1975 
Phenylbutazone Oxidation 0'Malley etal., l91l,Thggsetal., 1975, Fnenylbutazone OxidaUon whittaker and Evans, 1970 
Phenytoin Oxidation Hayes et al., 1975, Shewin et al.，1974 
Imipramine Oxidation Nies etal., 1977 
Amitriptyline Oxidation Nies etal., 1977 
Paracetamol Glucuronidation, Triggs et al., 1975, Briant et al., 1976 
(acetaminophen) sulphation Fluton et al., 1979, Divoll et al., 1982 
Amobarbital Oxidation lwmQetal, 1974 
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Table 4.2 Previous studies on the effect of age on liver drug metabolizing enzymes 
in animals 
Enzyme studied Effect of aging References 
Aldrin epoxidase (AE) Decreases activity Wynne etal, 1987 
Catalase Less resistant to heat Ando et al, 1997 
CYP1A1 Decreased inducibility of Horbach etal., 1990 
the corresponding m R N A 
CYPlA2 Decreased inducibility of Horbach^/a/., 1990 
the corresponding m R N A 
rvP2Rl Decreased expression rate Agrawal and Shapiro, 
ofits m R N A 1 ^  
CYP2B2 Decreases activity Shimada et al., 1995 
CYP2C11 Decreases activity N a k a j i m a . / a / . 1 9 9 ^ ^  
Shimada etaL, 1995 
CYP2C12 Increases activity Shimada et al.，1995 
CYP2C13 Increases activity Bandiera et al., 1986 
CYP2C7 Increases activity Bandiera et al., 1986 
CYP2E1 Decreases activity Nakajima etal, 1992 
C Y P 3 A Decreased inducibility by Lee and Werlin, 1995 
dexamethasone  
CYP3A2 Decreases activity Shimada etal, 1995 
— CYP2P1 Decreases activity Shimada et al., 1995 
^ C y t o c h r o m e P 4 5 0 ^ Decreasesactivity Guo,,a/., 1993 
reductase  
Cytochrome P450s Less resistant to heat Ando et al., 1997 
DT-Diaphorase N o effect — Guo etal, 1993 
Ejhoxyresof^j- ^Decreases activity""" W y n n e ^ l 9 8 7 
deethylase (EOR) 
Glutathione ^ -transferase ^ f^f^ t^ Guo etaL, 1993 
(GST) —  
A/-nitrosodimethylamine Decreases activity in Guo etal, 1993 
demethylase C N D M A d ) female mice  
Pentoxyresorufin 0- Decreases activity in Guo etal, 1993 
dealkylase (PROD) female mice  
Sulphotransferase N o effect Guo etal., 1993 
UDP-Glucuronosyl- N o effect Guo etal., 1993 
transferase  
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aging. Hunt et al. (1990) also sought to define potential aging-related 
alterations in CYP2E1, by examining the activity of this isoform in vitro, in 
liver microsomal samples obtained at surgery from patients age 60-75, and 
comparing these results to those obtained in liver microsomes prepared in 
younger subjects, age 30-59. The activity of hepatic CYP2E1 was again 
unaffected by normal aging. Another extended study (Schmucker et al., 1990) 
also demonstrated that there was no significant difference in the microsomal 
concentrations of several cytochrome P450 isozymes with aging. Also, the 
activity of the human hepatic cytochrome P450, CYP3A, was quantified in 
vitro as erythromycin N-demethylation in microsomes prepared from 43 
resected human liver specimens obtained from patients, age 27 to 83, with 
normal liver function. It was not surprising that the activity of C Y P 3 A did not 
correlate with age and other factors: smoking status, ethanol consumption, etc. 
(Hunt et aL, 1992). Moreover, one study showed a negative correlation 
between age and total cytochrome P450 content, NADPH-cytochrome c 
reductase activity and levels of CYP2E1 and 3A proteins, although the 
CYPlA2 and 2C proteins were unaltered with advancing age (George et al., 
1995). These results were different to the results in animal studies, and 
therefore more extensive study for the dmg metabolizing enzymes in human 
liver is needed. Moreover, no study has been done on the effect of age on the 
activity of flavin-containing monooxygenase--another important drug 
metabolizing enzyme, in human liver. F M O may show similar or different 
patterns of the effects of age when compared to cytochrome P450s, which has 
not been considered before. Therefore, we reported the results of the age 
effect on liver F M O activity in a Chinese population, using urinary T M A as 
the probe. 
Besides the age factor, the metabolism of drugs and other xenobiotics could 
also be influenced by a variety of factors including dietary intakes (Campbell 
and Hayes, 1974; Peterson and Holtzman, 1980). The effects of diet on dmg 
metabolism have been studied in both animal models and recently, in humans. 
Those studies include: the effects of food on the bioavailability of drugs, the 
identification of special dietary components that can influence drug 
metabolism, and the effects of those dietary components on enzyme activities. 
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Since the major enzyme systems responsible for drug metabolism also 
transform other exogenous chemicals and xenobiotics, e.g. carcinogens 
(Conney, 1986; Kuntzman et al., 1964), change of enzyme activities for those 
substances can indicate the diseases or deficiencies of factors in individuals 
with altered drug metabolism and disposition. 
Differences in food intake, both in amount and type, have been shown to alter 
the bioavailability of several antihypertensive drugs such as propranolol and 
metoprolol (Melander et al., 1977; Melander, 1978). However, other studies 
had shown that food reduced the absorption of many antibiotics, e.g. isoniazid, 
rifampicin, penicillin, ampicillin and tetracycline, and had no effect on the 
bioavailability of other drugs (Melander, 1978; Welling, 1977). Factors that 
influence the bioavailability of drugs include direct binding of drugs by food, 
or by altering luminal pH, gastric emptying, intestinal transit, mucosal 
absorption, splanchnic-hepatic blood flow, etc. (Anderson, 1988). Dietary 
influences on the microflora in the intestine may be another factor to affect the 
bioavailability of drugs when the drugs undergo metabolic transformation by 
these microorganisms (Scheline, 1973). Dietary macronutrients such as 
proteins, lipids, and carbohydrates also showed significant effects on drug 
metabolism. The metabolisms of antipyrine, theophylline, and propranolol in 
high carbohydrate, in high protein, and/or in high fat diets were studied in 
human subjects. It was found that substitution of protein for either fat or 
carbohydrate increased dmg oxidation rates (Alvares et aL, 1976; Anderson et 
al., 1979 & 1982; Fagan et aL, 1987; Kappas et al., 1976). Other reports 
showed that increased amounts of polyunsaturated oils in diets increased the 
cytochrome P450 and mixed function oxidases activities, while the lipid-free 
diets decreased their activities (Davidson and Wills, 1974; Marshall and 
McLean, 1971; Norred and Wade, 1972). The reason is the B-position fatty 
acid in phosphatidylcholine is highly unsaturated, and this phospholipid is 
essential to maintain the integrity of microsomal membrane. Amino acids, 
e.g. tryptophan increased liver protein synthesis and induced the mixed 
function oxidase system in animals and in liver cell cultures (Evarts and 
Mostafa, 1981; Paine, 1976; Sidransky，1986). High carbohydrate intakes 
resulted in a decreased cytochrome P450 activity and rate of drug metabolism 
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in animals (Campbell and Hayes, 1974), but had an inhibitory effect on a-
aminolaevulinate synthetase (Tschudy, 1978). Ascorbic acid deficiency 
impaired drug metabolism and reduced cytochrome P450 activity in laboratory 
animals (Holloway and Peterson, 1984; Horio et aL, 1986). Brodfuehrer and 
Zannoni (1986 and 1987a) found that deficiency in ascorbic acid in the diet 
also led to a reduction in F M O activity. They also confirmed that reduction in 
hepatic F M O activity was not related to stress (Brodfuehrer and Zannoni, 
1987b). Moreover, polynuclear aromatic hydrocarbons (PAH) are commonly 
present in processed food due to incomplete combustion and pyrolysis of 
petroleum and coal; some of them are carcinogens. Charcoal-broiled meat is a 
typical food containing PAH. Since drug oxidations in smokers are enhanced 
by these chemicals (Jenne et al., 1975; Kuntzman et al., 1977; Pantuck et al., 
1974), it seems the charcoal-broiled beef might also increase the rate of drug 
metabolism. This hypothesis was confirmed in the studies of antipyrine, 
theophylline, and phenacetin metabolisms, in which the subjects were fed with 
charcoal-broiled beef (Conney et al., 1976; Kappas, A., 1978). Certain 
indoles, present in cruciferous vegetables such as brussels sprouts, cabbage, 
and cauliflower, had been found to induce oxidations (Loub et al., 1975; 
Pantuck et al., 1976). Those effects on drug oxidations and conjugations have 
been investigated in human subjects, where the metabolism of antipyrine and 
phenacetin were markedly increased and the mean ratio of conjugated N-
acetyl-p-aminophenol was also increased (Pantuck et al., 1979). Moreover, 
ingestion of cabbage and brussels sprouts also increased the glucuronidation 
and metabolic clearances of paracetamol (Pantuck et al., 1984). However, 
paracetamol metabolism due to drug conjugation was not affected in subjects 
fed with charcoal-broiled beef (Anderson et al., 1983). 
Although many studies have been carried out to investigate the effects of diet 
and dietary components on enzyme activity involved in drug metabolism (see 
last paragraph), few investigations studied the effects on the F M O activity. 
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Therefore, it is not known whether the activity of F M O may be affected by 
dietary factors in normal subjects or in unaffected subjects with heterozygous 
trimethylaminuria. Since many types of food contain large amounts of 
trimethylamine (TMA), trimethylamine iV-oxide (TMAO) or their precursors, 
high intake of those foods may alter the activity of F M O in A^ -oxidation of 
T M A in these subjects. As described in Table 1.1, fish is a major source of 
T M A and T M A O , while meat and meat products, e.g. beef, lamb, also contain 
carnitine. Cauliflower, egg, soybean, and their products also contain choline 
and lecithin, which are precursors of T M A , generating T M A in vivo through 
the conversion of gut bacteria (Fig. 1.3) (De La Huerga and Poper, 1951; 
Prentiss et al., 1961). High intakes of T M A , T M A O , and their precursors 
produce high levels of free T M A in the gut by enterobacterial degradation. 
Conversely, some Brassica species and cruciferous vegetables, including 
cabbage, cauliflowers, Brussel sprouts, and swedes also contain progoitrin, 
which is an inhibitor of F M O enzyme (Fig. 4.1). Intake of these vegetables 
may lead to the inhibition of T M A A^ -oxidation (Fenwick et aL, 1982; Oginsky 
et al., 1965). It was uncertain whether the consumption of these vegetables 
led to secondary trimethylaminuria in man (Fenwick et cd., 1983; Al-Waiz, 
1988), although Pearson et al (1978) demonstrated in a breed of chicken with 
a genetically reduced ability to A/-oxidize T M A that further impairment in 
T M A 7V-oxidation occurred when fed with Brassica rapeseed meal. Another 
report showed that a high intake of milk from cows fed from a wheat pasture 
with significant levels of T M A O produced trimethylaminuria in a 10-year-old 
boy (Rothschild and Hansen, 1985). The present study was carried out to 
investigate the effects of diets and the dietary components on F M O activity by 
measuring the T M A and T M A O in a Chinese population. The F M O activity 
was then correlated with the subjects' age and dietary intake during the urine 
sampling period. 
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4.2 Experimental protocols 
4.2.1 Effect of age on TMA N-oxidation 
Urine sample collection procedures were carried out during the 
population study as described in Section 3.2. Data were collected after 
G C analysis. Both 24-hr and spot samples were analyzed. In the 24-hr 
urine collection, urine samples were collected during the four periods 
(midnight to wake up and before breakfast; after breakfast and before 
lunch; after lunch and before dinner; after dinner and before bedtime). 
These samples were used to determine the effect of age on the changes 
of urinary T M A , T M A O and percentage T M A A^ -oxidized during the 
24-hr period. However, the whole day values of percentage T M A N-
oxidized in 24-hr urine collection were combined with the values of 
percentage T M A 7V-oxidized in spot urine tests for the investigation of 
the effect of age on T M A iV-oxidation only. Data were analyzed by 
suitable statistical analysis tool pack (SigmaStat). 
4.2.2 Effect of diet on TMA N-oxidation 
The effect of diet on T M A 7V-oxidation was also based on the urine 
samples obtained from the population study. The information provided 
by the volunteers in the questionnaires in the 24-hr urine collection 
protocols (Section 3.2.1) and data obtained from Period 1 and Period 4 
in 24-hr urine collection protocols were used for analysis, details of 
which were described in Table 4.3. Based on the major types of food 
intake at the dinner, individuals were classified into several food 
groups: seafood, beef, chicken, and low-TMA diets. Some data had 
been omitted in the dietary study due to the reasons listed in Table 4.4. 
Amounts and rates of T M A and T M A O excretion in urine and the 
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Table 4.3 Schedules for urine collection in Periods 1 and 4 (24-hr urine 
collection protocols) 
Period 1 Period 4 
Dining Time 8:00 p.m., Day 0 8:00 p.m., Day 1 
Urine Collection 12:00 a.m., Day 1 to 8:00 p.m., Day 1 to 
Time 7:00 a.m., Day 1 ll:59p.m.,Day 1 
Duration 7 hours 3 hours 
Table 4.4 Reasons that the data should be omitted in the statistical 
analysis for dietary effect 
Examples 
Reason Types of food taken Amounts 
hcomplete (Blank) (Blank) 
questionnaires for diets 
Information is too rough Seafood dinner Heavy 
and general Hot-pot dinner Little bit 
Beef (Blank) 
Amounts of food taken T^ . , ^ , ^ 
Fish Enough amount 
werenotspecified chicken Very little 
Dietary intake was too .Qv^eftetfTalad Too complicate to 
complicated ^^ '^^ ‘^‘ b e ^ saiad, 
garoupa, jelly, ice- ^ 
cream)  
Insufficient size for Roast Lamb (n = 1) N/A 
statistical analysis Beancurd (n 二 2) N/A 
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percentage of T M A iV>oxidation were determined. Moreover, an 
arbitrary number between 1 to 10 (i.e. 1 = very little amount, 10 = very 
heavy amount) was assigned to each dietary component, according to 
the amounts of dietary components taken by the volunteers. The 
assigned number helped to select and group the subjects into suitable 
food groups. 
4.2.3 Effect of control diet on TMA N-oxidation 
Five volunteers were recruited in this study for three consecutive days. 
Urine samples were collected and volumes of excretion were measured 
over this period. Different types of foods were taken at each dinner to 
evaluate the effects on T M A 7V-oxidation. Only foods containing 
insignificant amounts of T M A , T M A O , or their precursors were taken 
by the volunteers between the dinners (Appendix B). Table 4.5 
describes the major foods to be taken by the volunteers during the 
experiment. The amounts and rates ofTMA, T M A O excreted, and the 
percentages T M A oxidation in urine samples were analyzed. 
Table 4.5 Major types of food intakes at dinners during the three-day 
control experiment 
Dinning Time Major Food Intake 
Day 0 Shrimp, 400 g; 
Garoupa, 200 g 
Day 1 Beef, 500 g 
Day 2 Chicken Meat, 500 g 
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4.3 Results 
4.3.1 Effect of age on TMA N-oxidation 
The amounts of T M A excreted in the 24-hr urine collection protocols 
in different age groups are described in Figure 4.2. Results of T M A O 
excreted (as T M A ) in the 24-hr urine collection protocols in different 
age groups are described in Figure 4.3. The results indicated that some 
age groups showed statistical differences at certain periods for T M A (jf 
< 0.05: age 18-30 vs age 41-50 at Periods 1 and 2, age 18-30 vs age 
51-64 at Period 3, age 31-40 vs age 41-50 at Period 4; p < 0.01: age 
18-30 vs age 41-50 at Period 4) and/or T M A O (as T M A ) Q? < 0.05: 
age 18-30 vs 41-50 at Periods 2 and 4, age 18-30 vs age 51-64 at 
Period 3, age31-40 vs age 51-64 at Periods 3 and 4; p < 0.001: age31-
40 vs age 41-50 at Period 4) excretion. However, those differences 
appeared randomly rather than following a specific trend. The % T M A 
excreted as T M A O in urine from spot urine tests and whole day urine 
collections were also combined together. The combined data for % 
T M A excreted as T M A O in different age groups (Fig. 4.4) showed that 
age 31-40 produced the lowest value (96.2 土 2.9 %; mean 士 s.d.) and 
age 41-50 produced the second lowest value (96.4 士 2.5 % ) in the 
percentage T M A 7V-oxidation. When Mann-Whitney U-test was 
performed, age 31-40 showed statistical difference compared to age 
18-30 and age 51-64 {p < 0.05). Also, age 41-50 showed statistical 
difference when compared to age 51-64 {p < 0.05). 
Spearman rank order correlation was also performed to investigate the 
effect of age on the whole day T M A and T M A O (as T M A ) amounts. 
It was found that no apparent correlation occurred between age and 
T M A (correlation coefficient = 0.136, p > 0.05) or T M A O (as T M A ) 
(correlation coefficient = 0.012, p > 0.05) amounts (n 二 159). On the 
































































































































































































































































































































































































































































































































































































































































































































combined data of the percentage T M A excreted as T M A O in urine to 
the age of volunteers (normality test failed, p < 0.001, n = 270). It was 
found that there was no observed correlation between age and the 
percentage value (correlation coefficient = -0.08,p > 0.05). 
4.3.2 Effect of diet on TMA N-oxidation 
According to the major types of food intake, four groups of diets were 
classified for analysis: seafood, beef, chicken, and low-TMA diet. 
'Low-TMA' diet represents the type of food taken that does not contain 
seafood, beef or chicken and no foods with T M A , T M A O , and T M A 
precursors. The percentage T M A excreted as T M A O at Periods 1 and 
4 in the four food groups are shown in Figs. 4.5 and 4.6, respectively. 
Seafood diet showed the highest percentage T M A excreted as T M A O 
in urine at both periods (98.2 土 1.9 % at Period 1, 97.6 土 2.5 % at 
Period 4; mean 土 s.d.), while the low-TMA diet showed the lowest 
values (96.6 士 2.5 % at Period 1, 95.2 土 2.9 % at Period 4). At Period 
1, Mann-Whitney U-test showed that the percentage of T M A excreted 
as T M A O in the seafood diet group was significantly higher than the 
other three diet groups Q? < 0.05). At Period 4, the percentage value of 
the seafood diet group only showed significant difference when 
compared to the 'Low-TMA' diet Q? < 0.005), but no difference to the 
beef and chicken diet groups {p > 0.05). Spearman rank order 
correlation analysis was also performed to assess any correlation 
between the amount of T M A excreted (TMA), the amount of T M A O 
excreted (TMAO), the rate of T M A excreted (TMAy'hr), and rate of 
T M A O excreted (TMAO/hr) to the % T M A A^ -oxidation (% T M A 
excreted as T M A O ) (Table 4.6). All four factors (TMA, T M A O , 
TMA/hr, TMAO/hr) showed positive correlation to the % T M A 
excreted as T M A O . However, only the factors T M A O , and TMAO/hr 
showed outstanding positive correlation (correlation coefficient > 0.76, 
























































































































































































































































































































































































factors, T M A and TMA/hr only had limited correlation coefficients (< 
0.5). 
Multiple linear regression analysis was performed on those factors to 
detect any simple positive or negative effect on the % T M A N-
oxidation (Table 4.7). Except for the factors T M A and TMAy^r Q?= 
0.1) at Period 1, all other factors had significant negative/positive 
effects (p < 0.001) on the % T M A iV-oxidation (% T M A excreted as 
TMAO). In order to predict the effects of these four food groups on 
the % T M A 7V"Oxidation, multiple linear regression analysis was 
performed again and an arbitrary number 1 or 0 was assigned on the 
subjects (Period 1, n = 98; Period 4, n = 88), to represent the intake of 
those foods or not (Tables 4.8 & 4.9). The results showed that seafood 
diet produced prominent positive effects on the percentage T M A 
excreted as T M A O , amount of T M A excreted, amount of T M A O 
excreted, rate of T M A excreted, and rate of T M A O excreted. The p 
values were less than 0.005 in all the five regression equations at either 
period. Regression coefficients for seafood also produced higher 
values when compared to beef diet or chicken diet. Therefore, seafood 
appeared to be the major source o f T M A and T M A O . 
4.3.3 Effect of control diet on TMA N-oxidation 
Five volunteers (A to E) took part in this three-day experiment. The 
following graphs describe the amounts of T M A and T M A O excreted 
(Fig. 4.7), rates of T M A and T M A O excreted (Fig. 4.8) and the 
percentage T M A A^ -oxidation (Fig. 4.9), in one typical volunteer (A). 
The results showed that the amounts of T M A (0.6 mg) and T M A O 
(117.9 mg as T M A ) excreted were suddenly increased after intake of 
seafood (Fig. 4.7). The rate of T M A O excreted (15.7 mg/hr as T M A ) 
showed a sudden increase while the rate of T M A excreted (0.1 mg/hr) 
was decreased after intake of seafood (Fig. 4.8). Other foods did not 
show significant effect on the amounts of T M A and T M A O excreted 
and on the rates of T M A and T M A O excreted. The percentage T M A 
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Table 4.6 Spearman rank order correlation analysis for the factors to the 
percentage T M A 7V-oxidation (Each box contained correlation 
coefficient and the p value) 
% T M A excreted as T M A O 
Period 1 Period 4 
(n = 98) (n = 88) 
™ 續 0.212 
{p < 0.005) Qp < 0.05) 
^ i ^ C.812 0.783 
Qr7<0.001) 0?<0.001) 
TA/TA/^ u 0.323 0.187 
画 虹 (p<0.005) (p = 0.08) 
TMAO/hr ( 0 . 8 :、 ( 0 . : 、  
O^<0.001) Qp<0.001) 
Table 4.7 Multiple regression analysis for factors on % T M A A^ -oxidation (%  
T M A excreted as T M A O ) at Periods 1 & 4 
Period 1 Period 4 
(n = 98) (n = 88) 
% T M A excreted as T M A O = % T M A excreted as T M A O = 
97.12 — (0.74 X T M A ) + (0.01 x 96.76 - (2.26 x T M A ) + (0.04 * 
T M A O ) (r = 0.435) T M A O ) (r = 0.586) 
T M A T M A O T M A T M A O 
O = 0.1) O<0.001) (^<0.001) (^<0.001) 
% T M A excreted as T M A O = % T M A excreted as T M A O 二 
97.19 - (6.59 X TMA/hr) + (0.11 96.72 - (9.12 x TMA/hr) + (0.19 
X TMAO/hr) (r = 0.413) x TMAO/hr) (r = 0.590) 
TMAy^hr TMAO/hr TMA/hr TMAO/hr 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































excreted as T M A O was also increased (> 99.5 % ) after intake of 
seafood (Fig. 4.9). 
The mean excretion rates of T M A and T M A O at different periods in 
this three-day experiment were plotted in Figure 4.10. Intake of 
seafood not only increased the rate of T M A O excreted at the first 
period (9.6 mg/hr.), it also produced a persisting effect over the 
following periods (gradually decreased from 4.4 mg/hr at Period 2 to 
0.7 mg/hr at Period 7; p < 0.05 when compared Period 1 with Periods 3 
to 7). On the other hand, there was no significant change for the rate 
of T M A excretion (p > 0.05). Figure 4.11 also described the mean 
percentage of T M A excreted as T M A O at different periods in this 
three-day experiment. Similarly, Period 1 (intake of seafood) showed 
the highest percentage T M A excreted as T M A O in urine (99.2 士 0.3 
% ) during the experiment. On the other hand, Table 4.10 described the 
results obtained from Spearman rank order correlation. All four 
factors: amounts of T M A and T M A O excreted, rates of T M A and 
T M A O excreted showed positive correlation with the percentage T M A 
excreted as T M A O in urine {p values < 0.05). 
4.4 Discussion 
Based on the data obtained in this study, it was found that some age groups 
showed statistically significant differences for T M A or T M A O (as T M A ) 
excretion at certain periods, when compared to other age groups (see footnotes 
in the figures). However, the differences appeared randomly rather than 
following a specific trend. For example, the youngest age group (age 18-30) 
showed a statistically significant difference in the T M A O amount excretion 
(Fig. 4.3) at Period 2 and at Period 4 when compared with the group: aged 41-
50，but this difference did not occur at Period 1 and at Period 3. Moreover, the 
pattern of differences in T M A O excretion could not be reproduced in T M A 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.10 Spearman rank order correlation analysis for the factors to 
the percentage T M A #-oxidation in three-day control 
experiment (Each box contained correlation coefficient and 
thep value). 
% T M A excreted as T M A O 
0.389 
T M A 
0^<O.O5) 
0.879 









4.2). One possible reason was the over-representation of the youngest age 
group, since most volunteers were belonged to this age group (〜70 % ) and 
only 10 % of the volunteers were at age 41 or above. Also, the effect of age 
on T M A and T M A O excretion might be masked by other factors, e.g. dietary 
factors or other unknown factors, and the true patterns may then not be seen in 
this study. Therefore, a study with controlled diet should be carried out for the 
investigation of the effect of age on T M A A^-oxidation. 
Since Kruskal-Wallis One W a y A N O V A on Ranks was performed (Chapter 
3), the data showed no difference for spot urine collections and for whole day 
urine collections. The sets of data were combined and the percentages of 
T M A excreted as T M A O in different age groups are plotted in Figure 4.4. It 
produced interesting results that the two middle-age groups (age 31-40, and 
age 41-50) produced the lowest percentage of T M A 7V-oxidation when 
compared to the youngest and oldest age groups (p < 0.05, refer to the footnote 
in Fig. 4.4). A U-shaped change for the % T M A oxidation versus age 
occurred. On the other hand, as described at the result section, the Spearman 
rank correlation showed no correlation between age and the percentage of 
T M A 7V"Oxidation (Section 4.3.1). This showed that the effect of age on the 
ability of T M A 7V>oxidation might not increase or reduce in a linear or 
logarithmic format. Since T M A is the substrate for flavin-containing 
monooxygenases (FMOs), especially for liver F M O , it is reasonable to 
extrapolate the data to human F M O activity. Therefore, the effect of age on 
the F M O activity might not reduce or increase linearly or logarithmically. 
However, other factors, possibly dietary factors, or other unknown factors, 
may be present to influence the T M A TV-oxidation in the two middle-aged 
groups. 
Many studies have shown that the ability for drug metabolism by Phase I 
enzymes (oxidation) decreased with aging (Table 4.1). In this study, there was 
no direct relation of F M O activity as shown by T M A A/-oxidation with age. 
The results were contradictory to the results obtained in animal studies. Many 
studies in animals showed that aging can decrease the activity of enzymes (e.g. 
cytochrome P450s) and in drug metabolism by Phase I oxidation (Tables 4.1 
94 
& 4.2). However, it was not surprising that when comparing the results to the 
data obtained in previous studies of human enzymes including cytochrome 
P450s (Section 4.1, paragraph 2). Many studies showed that drug 
metabolizing enzymes including cytochrome P450s (e.g. CYP3A2, CYP2C7) 
did not alter with advancing age. The decline in drug clearance might be 
caused by a fall in liver volume, blood flow, renal insufficiency, etc. (Table 
4.11) (Vestal and Dawson, 1985; Wynne et al., 1988). Therefore, the 
extrapolation of animal data to human might not be applicable. Although the 
current study showed that the liver F M O activity (using T M A #-oxidation as 
the probe) may change with age in a U-shape, more extensive study is needed 
because only limited studies have been done before on the effect of age on 
F M O activity and the numbers of subjects in some age groups were limited. 
In conclusion, there was no direct correlation between age and F M O activity 
in the Chinese population studied. The reduced ability for drug metabolism 
might not be related to enzyme activity or affinity directly, but may be related 
to other factors including changes in liver blood flow, mass, renal 
insufficiency, etc. (Table 4.11). To date, there has been relatively little 
information and work carried out on FMOs. Therefore, other types of study, 
such as measurement of liver F M O activity and its amount in liver biopsy, 
should be carried out. A longitudinal study may be carried out to look at the 
change of the F M O ability for T M A iV-oxidation throughout the lifetime of the 
volunteers, although this type of study would be time-consuming and difficult 
to perform. 
In the study of diet on the T M A iV-oxidation and in analyzing the data 
obtained in 24-hour urine collection protocols, Period 1 and Period 4 were 
studied since urine collections were started after the dinners. Although Period 
1 was started four hours after the first dinner but Period 4 was started just after 
the second dinner (Table 4.3)，results were useful to show the prolonged 
effects and excretion characteristics after intake of foods (and intakes of T M A , 
T M A O , and the precursors). On the other hand, Period 4 showed the 
immediate effects and excretion characteristics of the above factors. It was 
clear that intake of seafood produced the highest percentage of T M A N-
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Table 4.11 Factors affecting drug disposition in elderly patients (modified 




3) Congestive heart failure 
4) Dehydration 
5) Diarrhea 
6) Edema or ascites 
7) Fever 
Disease 8) Hepatic failure 
9) Hepatic insufficiency 
10) Hypovolemia 




15) Renal Failure 
16) Renal insufficiency 
17) Thyroid disease 
18) Viral infection or immunization 
1) Decreased absorptive surface 
2) Decreased cardiac output 
3) Decreased gastrointestinal motihty 
4) Decreased glomerular filtration rate 
5) Decreased lean body mass 
6) Decreased liver blood flow 
7) Decreased liver mass 
Physiological change 8) Decreased renal blood flow 
9) Decreased serum albumin 
10) Decreased splanchnic blood flow 
11) Decreased total body water 
12) Decreased tubular secretion 
13) Increased body fat 
14) Increased gastric pH 




Therapeutic and 4) Dietary composition 
environmental factor 5) Drug interactions 
6) Food or meals 
7) Insecticides 
8) Protein-binding displacement 
9) Smoking 
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oxidation in urine in both periods (98.2 % at Period 1; 97.6 % at Period 4). 
The results obtained in Figures 4.5 and 4.6 showed some differences, although 
the low-TMA diet showed the lowest percentage of T M A A^ -oxidation, and 
beef and chicken diets produced intermediate values. In Period 1, a statistical 
difference (Mann-Whitney U-test) was observed when the seafood diet was 
compared to all other three types of foods. Thus, high intake of T M A and 
T M A O through seafood consumption increased the percentage of T M A TV-
oxidation and had persisting effects on this oxidation and excretion several 
hours after the diet intake. High amounts of T M A and T M A O from seafood 
took time to inter-convert in the gut (by bacteria) and to oxidize by liver 
FMOs. On the other hand, it has been suggested that under heavy T M A 
exposure conditions (consumption of seafood) and the consumption of 
vegetables containing inhibitors of the T M A oxidase, features of the fish-
odour syndrome may occur in carriers on a sporadic basis (Ayesh and Smith, 
1992). Therefore, apart from oral T M A dosage, intake of seafood may be a 
good alternative to investigate the deficiency of T M A A^ -oxidation, the activity 
of F M O s on T M A 7V-oxidation, and the genetic condition of 
trimethylaminuria. It may be useful for the subjects who had mild impaired 
ability in T M A A^ -oxidation, i.e. secondary trimethylaminuria by genetic 
problem, disease, and other environmental factors. In Period 4, however, no 
short term statistical difference was obtained for seafood, beef, and chicken 
intakes. It could be explained because urine samples at Period 4 were 
collected just after the intake of food. Beef and chicken diets, although not 
containing high amounts of T M A and T M A O as in seafood, contain certain 
amounts of carnitine and choline. These precursors were converted to T M A O 
by gut bacteria and excreted through the urine. Therefore, the percentages of 
T M A 7V-oxidation were similar in seafood, beef, and chicken diets at the four 
hour periods after taking those foods, because the initial intakes of T M A , 
T M A O or the precursors stimulated the initial activity of F M O . After these 
four hours, the excreted amounts of T M A O from beef and chicken were 
expected to reduce since most of the carnitine and choline were already 
depleted. At that moment, only the seafood diet (containing very high 
amounts of T M A and T M A O ) still produced high T M A O excretion in urine 
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and a high percentage of T M A A^ -oxidation. This explanation was supported 
by the results obtained in Period 1 (Fig. 4.5). 
In Spearman rank order correlations for the amounts of T M A (TMA) and 
T M A O (TMAO) excreted, rates of T M A (TMAy^hr) and T M A O (TMAO/hr) 
excreted, to the % T M A iV-oxidation (% T M A excreted as T M A O ) in both 
periods, as described in Section 4.3.2, all four factors (TMA, T M A O , TMAy%, 
TMAO/hr) showed a positive correlation to the % T M A excreted as T M A O , 
but only the factors T M A O and TMAO/hr showed outstanding positive 
correlation (correlation coefficient > 0.76, p < 0.001) to the % T M A excreted 
as T M A O . Therefore these two factors should be useful to monitor the 
percentage change of T M A TV-oxidation in urine. In addition, multiple linear 
regression analysis showed that those factors (except T M A and TMA/hr at 
Period \,p = 0.1) had significant positive effects on the percentage of T M A TV-
oxidation {p < 0.001) (Table 4.7). The equations showed reasonable results 
that a decreased amount of T M A excreted and a decreased rate of T M A 
excreted at both periods should increase the percentage of T M A A^ -oxidation. 
The reason was most of the T M A was converted to T M A O , and therefore the 
percentage value o f T M A excreted as T M A O in urine was increased (Equation 
2.3). The effects of the four food groups on the percentage of T M A N-
oxidation were shown in Tables 4.8 & 4.9, using multiple linear regression 
analysis. According to the results shown in Tables 4.8 and 4.9, seafood diet 
produced prominent positive effects on the percentage T M A excreted as 
T M A O , amount of T M A excreted, amount of T M A O excreted, rate of T M A 
excreted, and rate of T M A O excreted {p < 0.005). Also, the regression 
coefficients for seafood also produced the highest values when compared to 
beef diet or chicken diet. It can be concluded that seafood was the major 
source of T M A and T M A O and this result also suggested that intake of 
seafood may be a good source to investigate the deficiency of T M A N-
oxidation, the activity of F M O s on T M A , and the genetic condition of 
trimethylaminuria. 
In the effect of control diet on T M A #-oxidation, the amounts of T M A and 
T M A O excreted were suddenly increased after the intake of seafood (Fig. 4.7). 
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The rate of T M A O excreted was increased but the rate of T M A excreted was 
decreased (Fig. 4.8). This feature was not reproduced after the intakes of other 
foods, which further support the hypothesis that F M O activity could be 
stimulated by high amounts of T M A and T M A O intake (from seafood). 
Therefore, the highest percentage of T M A excreted as T M A O in urine 
occurred immediately after the intake of seafood (Fig. 4.9). The raw data was 
not shown for the other four volunteers because the times for urination were 
different for the volunteers. However, all the volunteers showed similar 
results for T M A TV-oxidation. The mean values for the rates of T M A and 
T M A O excreted (Fig. 4.10) and the percentage of T M A A^ -oxidation (Fig. 
4.11) further confirmed that intake of seafood increased the rate of T M A O 
excretion and the percentage of T M A TV-oxidation (see data at Period 1). 
Also, a high intake of T M A O produced a persisting effect on the rate of 
T M A O excretion, and a decreased rate of T M A excretion. The results of 
Spearman rank order correlation in this control experiment also showed that 
the amount of T M A O excreted and the rate of T M A O excreted had 
outstanding positive effects on the percentage of T M A excreted as T M A O in 
urine (correlation coefficients > 0.87, p values < 0.001). 
From the results of the effects of diet and control diet on T M A A/-oxidation, it 
can be concluded that seafood is the major source o f T M A and T M A O . Intake 
ofseafood (as high intakes o f T M A and T M A O ) can stimulate the initial F M O 
activity and lead to a higher percentage of T M A 7V-oxidation. It also produced 
persisting effects on the rate of T M A O excretion and the percentage of T M A 
excreted as T M A O in urine. Therefore, it may be used as a medium, instead 
of direct T M A dosage, to investigate the subjects with impaired ability in 
T M A iV-oxidation, i.e. secondary trimethylaminuria. Moreover, there have 
been few studies conducted on the effect of diet on enzyme activity and drug 
metabolism together with a dietary survey. Only one similar study has been 
carried out before to determine the relationship of oxidative drug metabolism 
to food preference (Britto et al, 1991). In this study, the poor metabolizers of 
dextromethorphan showed a diminished stated preference for cauliflower and 
coconut, and poor metabolizers of mephenytoin showed a diminished stated 
preference for spinach and cabbage. Moreover, the 'unfavorable responses' to 
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those foods might be due to the presence of chemical components in those 
foods that caused inhibition to the corresponding cytochrome P450s. 
Therefore, the current study may be an additional source to show the effect of 
normal dietary intake on enzyme activity. 
According to the data obtained in this study, there was no direct correlation 
between age and F M O activity on the percentage T M A iV-oxidation, but the 
dietary study (dietary survey and controlled diet) showed that intake of 
seafood increased the F M O activity on the percentage T M A iV-oxidation. 
Thus, intake of seafood may be useful to investigate the subjects with 
impaired ability in T M A TV-oxidation. 
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5.1 Introduction 
The effect of disease on the pharmacodynamics and pharmacokinetics of drugs 
has been well documented. Diseases such as chronic liver disease and renal 
disease affect drug metabolism and lead to changes in the efficacy and 
duration of action of many drugs. Chronic liver disease has a major effect on 
drug metabolism in patients. Figure 5.1 describes the free exchange of fluid 
and substrates between the sinusoidal lumen and the space of Disse in a 
healthy liver. The mechanisms of impairment of hepatic drug elimination in 
chronic liver disease can be described by four different theories: the sick cell 
theory; the intact hepatocyte theory; the impaired drug uptake theory; and 
the oxygen limitation theory. Dosage requirements for drugs of both high and 
low hepatic clearance may be affected (Morgan and McLean, 1995). The sick 
cell theory envisaged a reduction in the content and activity of the hepatic 
drug metabolizing enzymes while blood flow is maintained. It was supported 
by the studies of a decrease in the hepatic extraction ratio of indocyanine 
green by functional hepatocytes (Perlik et al., 1992), and a correlation between 
systemic and intrinsic hepatic clearances of pethidine and morphine in 
cirrhotic rats (Callaghan et al., 1993). The second theory is the intact 
hepatocyte theory and it shows a reduced mass of cells, which function 
relatively normally and are normally perfused. It assumes the same fractional 
reduction in hepatocellular volume, with which the hepatic clearance of low 
clearance drugs is proportional, as the fractional reduction in functional 
hepatic blood flow rate (i.e. flow through remaining functional tissue), with 
which the hepatic clearance of high clearance drugs is proportional. It was 
proposed by the measurement of the liver volume in patients with cirrhosis by 
computerized topography (Kwasaki et al., 1992) and by liver biopsies from 
patients with cirrhosis (Meyer et al., 1991)，which showed unchanged 
clearance per hepatocyte in cirrhosis. The third theory is the impaired drug 
uptake theory. It proposes that the most significant feature of cirrhosis is the 
process of sinusoidal capillarization. Capillarization involves the formation of 





































































































































































macromolecular exchange (Martinez-Hernandez and Hernandez, 1991). The 
barriers are caused from loss of fenestration of the sinusoidal endothelium, 
development of basal laminae and deposition of complex macromolecules in 
the space of Disse. The fourth theory is the oxygen limitation theory due to 
the impaired uptake of oxygen across the capillarized endothelium (McLean 
and Morgan, 1991; Morgan and McLean, 1991). This theory was supported 
by the increased theophylline clearance in cirrhotic rats, but not in healthy rat, 
with inhaled oxygen supplementation (Hickey et al., 1995). Uptake of 
oxygen becomes the rate limiting step，rather than the drug uptake in impaired 
drug uptake theory. As a result, the impaired drug uptake theory is generally 
accepted to describe the impairment of hepatic drug elimination in chronic 
liver disease. On the other hand, studies also showed that moderate degrees of 
liver impairment can impair the renal drug clearance (McLean and Morgan, 
1991; Westphal and Brogard, 1993), and the renal elimination of drug 
metabolites was impaired by decreased renal blood flow and glomerular 
filtration. Renal disease is another major disease which interferes with the 
elimination of many drugs and it also affects drug metabolism. It not only 
reduces the renal clearance of drugs but also affects the nonrenal clearance of 
drugs (Farrell, 1987; Gibson, 1986, Touchette and Slaughter, 1991). Studies 
showed that multiple microsomal enzyme activities in animals were decreased 
with acute and chronic renal failure (Anders, 1980; Hogan et al, 1979; 
Patterson and Cohn, 1984; Terner et al., 1978). The decrease in total 
metabolic activity in intact animals with renal insufficiency may be due to the 
impairment of hepatic metabolic activity as well as the loss of renal 
metabolism. Therefore, drug clearance will be altered due to the effects on 
glomerular blood flow and filtration, tubular secretion, reabsorption and renal 
parenchymal mass. It leads to the need for alternations in dosage regimens to 
optimize therapeutic outcome and minimize the risk of toxicity. 
In view of the impairment of drug metabolism by liver and renal disease, 
decreased liver function including decreased liver F M O activity (sick cell 
theory) or the formation of continuous filtration and diffusion barriers 
(impaired drug uptake theory) may retard the TV-oxidation of T M A to T M A O 
in the liver (Ayesh and Smith, 1992; Marks et al., 1978; SimenhofF et al., 
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1977; Wills and Savory, 1981; Wranne, 1956). One piece of evidence was 
that liver cirrhosis increased the urinary excretion of T M A because of the 
impaired hepatocellular fiinction or the presence of portosystemic venous 
shunts, which might increase the systemic availability of T M A due to the 
decreased first-pass metabolism (Marks et al., 1978). Moreover, increased 
blood levels o f T M A and dimethylamine have been suggested to be one of the 
etiological factors in the development of hepatic coma in cirrhotic patients. 
Another piece of evidence was the increased excretion of T M A in a 3-year-old 
female with congenital intrahepatic portocaval shunt (Fernandez et al, 1997). 
This also confirmed that such a venous shunt is another factor to increase the 
systemic availability of T M A . Other diseases, such as diabetes may also alter 
the F M O activity and lead to a change in the percentage of T M A 7V-oxidation. 
Rouer et al (1988) reported that liver microsomal F M O activity assessed by 
thiobenzamide metabolism was increased by two-fold in streptozotocin-
induced diabetic (insulin deficient) rats and mice and, to a lesser degree in 
congenital insulin resistant Ob/Ob mice. It might therefore be expected that 
the percentage of T M A TV-oxidation in diabetic patients should have a 
different pattern when compared to normal subjects. According to the 
previous findings of T M A iV-oxidation and in F M O activity, it was possible to 
assume that patients with retarded liver function would show a low percentage 
value of T M A 7V-oxidation. Therefore, the present study evaluated patients 
with chronic liver disease and retarded liver function, and patients with 
diabetes, on the percentage of T M A 7V-oxidation, which may result from a 
change in F M O activity. The patterns of these diseases on T M A TV-oxidation 
were also compared with other diseases in patients with normal liver function 
(hyperlipidaemia treated with statins, hypertension treated with anti-
hypertensive drugs). Patients with hyperlipidaemia were chosen in this study 
because hyperlipidaemia is a disease associated with high plasma triglyceride 
and cholesterol levels caused by high intake of fat and cholesterol from the 
diet. The metabolism of fat involves a rather complicated pathway including 
the esterification of fatty acids to triglycerides in the liver. Triglycerides in 
very low density lipoprotein (VLDL) particles are also metabolized by 
lipoprotein lipase resulting transiently in intermediate density lipoprotein 
(HDL) particles which are taken up by the liver or converted by hepatic lipase 
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into low density lipoprotein (LDL) particles. Some lipid-lowering drugs, e.g. 
most of the lipid-soluble statins, that are used for the treatment of 
hyperlcholesterolaemia are metabolized by CYP3A4 (Stern et al., 1997). The 
drug interactions that have been described are mainly with other agents that 
inhibit this isoenzyme such as the macrolide antibiotics, the azole antifungals 
and cyclosporine. These interfere with statin metabolism and may increase 
the risk of myopathy. Although statins do not appear to have a major 
inhibitory effect on this enzyme, it is not unreasonable to consider that statins 
might affect other metabolic pathways and interfere with the function of other 
enzymes. Therefore, it is reasonable to examine the effect of hyperlipidaemia 
itself on the percentage of T M A 7V-oxidation, and additionally the effect of 
statin treatments. Moreover, one type of the statin: atorvastatin (Fig. 5.2 a), 
which is the most potent lipid-lowering drug was being evaluated in a clinical 
study at the time of this work. It can reduce the blood cholesterol by almost 
50 % . Currently, there is no information about the effects of this drug on 
F M O s and on T M A 7V-oxidation. It was therefore considered opportune to 
investigate the effects of this drug on T M A A^ -oxidation as the patient cohort 
was already available. Another drug, hydroxychloroquine (HCQ) (Fig. 5.2 b), 
which is one of the antimalarial agents, is commonly used in the treatment of 
systemic lupus erthematosus (SLE) because of its anti-inflammatory activity 
and steroid sparing effect (Hodis et aL, 1993). SLE is a chronic multi-organ 
systemic disease thought to be of autoimmune origin that affects young men 
and women in their twenties and thirties. H C Q is also used for the treatment 
of rheumatoid arthritis and it has been suggested that it might be useful as a 
treatment for hyperlipidaemia by inhibiting cholesterol synthesis through its 
effect on 2,3-oxidosqualene-lanosterol cyclase. On the other hand, there is no 
information about its effect on F M O activity and T M A 7V-oxidation. Similar 
to atorvastatin, the use of this drug might cause other unexpected side effects 
in other metabolic pathways, e.g. T M A iV-oxidation. A study had also been 
initiated to examine the effects of H C Q on lipid levels in a group of patients 
with SLE and the opportunity was taken to obtain urine samples from these 
subjects to study whether H C Q had any effect on T M A A^ -oxidation. 
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In the studies in this chapter, T M A 7V-oxidation was measured in groups of 
Chinese patients with various diseases (chronic liver disease, diabetes, 
hyperlipidaemia with statin treatments, and hypertension), and in two study 
cohorts to determine whether certain medications (atorvastatin, 
hydroxychloroquine) would alter the F M O activity by the measurement of the 
degree of T M A iV>oxidation. Although patients with hypertension have not 
been reported to have any change in T M A A^-oxidation, they have not been 
studied generally and they were included in this clinical screening study 
because a large number ofhypertension cases are seen in the hospital and they 
were readily available to study. 
5.2 Experimental protocols 
In the study of the effects of diseases and medications on T M A 7V"Oxidation, 
urine samples were collected from male and female patients at the Prince of 
Wales Hospital, Shatin, NT, Hong Kong. Spot urine samples or 24 hr urine 
samples were collected for analysis. The sample collection procedures were 
already described in Section 3.2, Chapter 3. As described in Section 5.1, four 
patient groups were studied: chronic liver disease (cirrhosis), diabetes, 
hypertension, hyperlipidaemia. Patients treated with atorvastatin or 
hydroxychloroquine were also investigated. Patients treated with atorvastatin 
had severe resistant hyperlipidaemia which had not responded adequately to 
previous therapy. They had been on treatment for 16 weeks at the time the 
first urine samples were collected. The dose of atorvastatin had been 
increased from 10 mg to 20, 40 then 80 mg in most patients at intervals of 4 
weeks. The second urine samples were collected in these patients after they 
had been off treatment for 4 weeks when plasma lipid levels had returned to 
pretreatment levels. The effect of hydroxychloroquine treatment was studied 
in a cohort of patients with SLE who were being studied to examine the effects 
of this drug on the lipid profile. The patients with SLE were attending the 
rheumatology clinic at the Prince of Wales Hospital. The diagnosis of SLE 
had been made according to the American Association of Rheumatology 
criteria. None of the patients had significant renal disease as determined by 
plasma creatinine levels. The patients attended in the morning fasting for 
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blood sampling. Spot urine collections were made at these visits. The results 
for T M A A^ -oxidation in those subjects who were maintained on 
hydroxychloroquine were compared with control subjects who were not taking 
hydroxychloroquine but were maintained on anti-inflammatory doses of 
corticosteroids (prednisone or prednisolone). 
Data were analyzed using the SigmaStat software (Jandel Scientific). 
Different groups were compared by analysis of variance, unpaired t-tests or 
non-parametric tests if the data were not normally distributed. Results for 
patients treated with atorvastatin were compared with the results after stopping 
treatment by paired t-tests. 
5.3 Results 
In the study ofthe effect of disease on T M A A^-oxidation, the percentages of 
TMA7V-oxidation for four different patient groups are described in Figure 5.3. 
Hyperlipidaemic patients treated with statins (n = 19; male = 9, female = 10), 
were of age from 23 to 70 years (46.7 士 13.3; mean 土 s.d.). They showed the 
highest percentage o f T M A excreted as T M A O in urine (96.3 士 2.8 %; mean 士 
s.d.). Hypertensive patients (96.0 士 2.8 %; n = 26; male = 11, female 二 15), 
age range from31-64 years (49.5 士 9.7), and diabetic patients (94.3 土 6.0 %; n 
=22; male 二 13，female = 9)，age range from 24 to 81 years (55.5 士 17.1) 
produced comparable percentage values to the hyperlipidaemia patients and 
there was no significant difference between these groups. However, patients 
with chronic liver disease (n = 20; male = 16, female = 4), age range from 37 
to 76 years (60.0 士 11.8) showed retarded ability in T M A A^ -oxidation. This 
group produced the lowest percentage value (85.8 士 5.3 % ) when compared to 
the other three patient groups and the data obtained from the normal subjects 
(Chapter 3) (p < 0.001, Mann-Whitney U-test). However, the other three 
patient groups (hypertension, diabetes, and hyperlipidaemia) did not show any 
statistical significance when compared with each other and to the normal 
subjects (Chapter 3) (p > 0.05, Mann-Whitney U-test). Moreover, the 












































































































































markedly when compared to normal subjects. Scattered plots for the 
percentage of T M A excreted as T M A O in urine in the four patient groups are 
shown in Figure 5.4. On the other hand, the details for the 20 patients with 
chronic liver disease are listed in Table 5.1. Some of these patients were also 
diabetic on oral hypoglycaemic drugs or insulin. Most subjects who excreted 
less than 90 % of T M A as T M A O showed abnormal high levels of total 
bilirubin (> 15 ^imol 1"^ ) and alanine aminotransferase (ALT) (> 58 RJ 1'^ ). 
The mean values of total bilirubin and alanine aminotransferase in these 20 
patients were 65.8 士 67.5 ^ imol 1"^  and 58.0 士 44.5 RJ 1"^  respectively (mean 士 
s.d.). 
Urine samples from 19 patients (male = 5, female = 14), age range from 32 to 
69 years (50.8 士 13.0, mean 士 s.d.), treated with atorvastatin were examined 
and compared with the samples from the same patients 4 weeks after stopping 
treatment. There was no significant effect on the percentage of T M A N-
oxidation (treated with atorvastatin: 94.3 士 3.4 % , ofF drug: 95.3 士 2.0 %; 
mean 士 s.d., n = \9,p > 0.05) (Fig. 5.5). 
Urine samples from SLE patients treated (age range from 21 to 52 years, 38.6 
士 7.6, mean 士 s.d.; male = 1, female = 45; n = 46) or without treatment (age 
ranged from 18 to 66, 40.5 土 11.4，mean 土 s.d.; male = 1, female = 23; n 二 24) 
with H C Q were analyzed. The treatment with H C Q for patients with SLE also 
had no significant effect on the mean percentage of T M A #-oxidation (with 
H C Q : 94.2±5.2o/o,mean±s.d.,n = 46;withoutHCQ: 94.5±2.5o/o,n = 24. 
p > 0.05) (Fig. 5.6). However, three female patients, who were on treatment 
with H C Q showed a relatively low percentage of T M A A^-oxidation, the 
percentage values were 78.3 % , 82.5 % , and 88.4 % respectively. These 
patients will be studied further to determine whether these findings are 
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Fig. 5.5 Percentage T M A 7V-oxidation for patients treated with atorvastatin and at off 
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Patients with chronic liver disease showed an impaired ability of T M A N-
oxidation in this study Q? < 0.001), while the other patient groups appeared 
normal (p > 0.05), when compared to normal volunteers. Although the 
patients with chronic cirrhosis had different extents of liver disease, most of 
them had severe liver damage. The damage produced elevated levels of 
bilirubin and alanine aminotransferase (ALT) (see Section 5.3, paragraph 1). 
Table 5.1 showed the clinical diagnoses, liver function tests and drug 
treatment information for this patient group. More than half the number of 
patients showed elevations of total bilirubin and alkaline phosphatase. 
Bilirubin comes mainly from red cell precursors within the bone marrow and 
from the breakdown of myoglobin. It is then removed from the body by the 
liver. Hyperbilirubinaemia is the result of severe hepatocellular damage 
during hepatitis or cirrhosis. Raised levels of ALT, which is a cytosolic 
enzyme, also known as serum glutamic pyruvic transaminase (SGPT), in the 
chronic liver disease patient suggests liver cell damage resulting in this 
enzyme leaking into the blood stream. The reasons for impaired T M A N-
oxidation in cirrhotic liver disease may be numerous pathophysiologic 
changes in the liver, similar to the impaired uptake theory described in Section 
5.1. The development of cirrhosis starts with initial hepatocellular damage 
that produces inflammation; dead or necrotic cells are removed by 
phagocytosis. Then, fibroblasts secret collagen to help maintain the integrity 
of the liver architecture, while the damaged or dead cells are repaired or 
replaced. Collagen fibrils accumulate in the sinusoidal space, including the 
space ofDisse, and produced bands of connective scar tissue characteristic of 
cirrhosis. Also, a basement membrane lacking in microvilli is produced at the 
sinusoidal surface of the hepatocyte. The collagen barrier between hepatocyte 
and sinusoid interferes with the exchange of nutrients, drugs, and the 
metabolites, between the blood and hepatocytes. Liver nodules might occur 
due to the regeneration ofhepatocytes and the compensation for hepatocellular 
damage. Therefore, the vascular resistance and portal venous pressure are 
increased, and extra- and inter-hepatic shunts develop. Blood could then 
bypass the fiinctioning hepatocytes and flow through these shunts into the 
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central veins. As a result, xenobiotics, drugs, and metabolites, e.g. T M A , 
might be less accessible to functional hepatocytes, which contain enzymes for 
normal metabolism, and the mean percentage of T M A 7V-oxidation in patients 
with liver disease was lower than that in the normal volunteers. Moreover, 
damage to hepatocytes might cause reduction of the amount and activity of 
liver F M O , which could also lead to a low mean percentage of T M A N-
oxidation. 
Although a previous study in rats showed that diabetes might affect F M O 
activity (Rouer et al., 1988)，the current study showed no apparent change in 
the percentage of T M A A^ -oxidation in patients with non-insulin dependent 
diabetes. Moreover, patients with hypertension who were treated with anti-
hypertensive drugs and patients with hyperlipidaemia who were treated with 
statins also showed no effect on the T M A A^ -oxidation. This suggests that, as 
expected, these diseases and these types of drugs are unlikely to have a major 
effect on hepatic F M O activity and the liver function for these patients was 
also normal. Although atorvastatin previously showed effects on cytochrome 
P450 activity, the present study with atorvastatin in patients with normal liver 
function showed that this statin did not affect the percentage of T M A TV-
oxidation {p > 0.05) (Fig. 5.5). As this is the most potent of the statins, it is 
unlikely that lowering of cholesterol by inhibition of hydroxymethyl-glutamyl-
C o A reductase per se will affect F M O activity, but it may not be appropriate 
to extrapolate these results to other statins which could have different direct 
effects on F M O . 
In the hydroxychloroquine (HCQ) study, the mean values for percentage T M A 
A^ -oxidation were similar in patients treated with H C Q to those that were not 
on H C Q treatment {p > 0.05) (Fig. 5.6). However, three female patients 
treated with H C Q showed a reduced percentage of T M A 7V>oxidation (78 - 88 
%). This raises the question as to why should these three patients have a lower 
percentage values than the other patients treated with H C Q . Did they have 
any other diseases or previous record of clinical problems? It is possible that 
they are heterozygous for a mutation in the F M O gene. Perhaps there are 
other factors in these patients which affect T M A TV-oxidation, such as the 
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vaginal conditions and menstruation. Females who are suffering from 
bacterial vaginosis showed higher T M A levels in vaginal discharge than 
control females (Brand and Galask, 1986; Sardas et al., 1996). Moreover, 
Zhang et al. (1996b) showed that in normal females as menstruation began, 
there was a marked depression in urinary T M A A^-oxide output with a 
reciprocal increase in the unchanged amine, signifying a decrease in T M A TV-
oxidation. These changes might be caused by hormonal modulation. 
Therefore, more clinical details will be obtained for the three female outliers 
in the H C Q study initially determining the menstrual history and whether there 
was evidence ofbacterial vaginosis. 
According to the results obtained in this study, patients with impaired liver 
function, i.e. chronic liver disease, showed an impaired ability in T M A N-
oxidation and this impairment may be caused by a reduction of liver F M O 
activity and/or shunting of blood from the portal to the systemic circulation. 
Other patients with normal liver function but a variety of other diseases and 
receiving various commonly used dmgs did not show any significant change 
in the ability of T M A 7V>oxidation. Therefore, it can be concluded that the 
impairment of T M A A^ -oxidation is principally related to chronic liver disease. 
Therefore, cautious prescribing is needed for the drugs that are metabolized by 
F M O in these patients. 
The two drugs studied, atorvastatin and hydroxychloroquine, showed no 
significant effect on T M A A^ -oxidation. These drugs were chosen for study 
because clinical studies with these agents were already planned and urine 
samples were readily available. It is possible that other drugs are more likely 






Inter-ethnic differences in drug metabolizing enzymes such as flavin-containing 
monooxygenase have been reported in numerous studies involving different ethnic 
groups (Chapter 1). Most ofthe studies on F M O and T M A 7V-oxidation were carried 
out in Caucasian populations and in several non-Caucasian populations. In this study, 
T M A 7V"0xidati0n was investigated in a Chinese population, to determine the F M O 
activity by measuring T M A A^ -oxidation. 
A simple and sensitive gas chromatographic method for T M A and T M A O 
(trimethylamine 7V-oxide) analysis in urine samples was developed (Chapter 2). By 
using the gas chromatograph with flame-ionization detector, the linear range of 
calibration curve was shown to be from 0.1 |ig/ml to 10 ^ ig/ml of T M A . The time for 
one injection was less than 10 minutes and this was an improvement in the time for 
analysis when compared to the old methods, i.e. more than 40 urine samples could be 
analyzed per day. The analytical method was validated. Intra-assay variation of the 
same urine sample in a single assay and inter-assay variation of the same urine 
samples over three months showed excellent results in repeatability (CoV % = 1.3 % 
for T M A , 3.7 % for T M A + T M A O (as TMA)) and in reproducibility (CoV % = 3.9 % 
for T M A , 2.4 % for T M A + T M A O (as TMA)). The % T M A conversion (Equation 
2.3) was chosen to represent the extent of T M A iV-oxidation, since the % T M A 
conversion was the accepted value to represent the ability of T M A A^ -oxidation in 
similar pharmacogenetic studies. 
The population study of T M A A^ -oxidation in a Chinese population was carried out 
using whole day urine collection method (24-hr urine samples). In addition, a spot 
urine collection method was also employed in which the subject provided one spot 
urine sample only. The results were analyzed in parallel in which the spot urine 
method showed comparable results to the whole day urine collection method {p < 
0.05). Therefore, the spot urine collection procedure is a simpler, but equally accurate 
method for the investigation of primary trimethylaminuria. The current study showed 
that none of the volunteers suffered from fish-odour syndrome (trimethylaminuria), 
but seven subjects (3 % ) excreted 80-90 % of T M A as T M A O and another two 
subjects (1 % ) excreted 74 % and 75 % of T M A as T M A O respectively. These 
subjects may have impaired ability of T M A A^ -oxidation due to genetic or other 
factors. The T M A load test was not performed in this study, and as such, remains a 
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limitation of the study because the T M A load test in these people with heterozygous 
defects in F M O (50 - 90 % T M A excreted as T M A O in urine) would be a useful 
confirmation. 
The effects of age and diet on T M A A^ -oxidation were also investigated in this study. 
Although it was found that some age groups showed statistical differences for T M A 
or T M A O (as T M A ) excretion at certain periods, when compared to other age groups, 
those differences appeared randomly rather than in a specific trend. Therefore, the 
amounts of T M A and T M A O excreted in the urine did not show any specific pattern 
related to age. On the other hand, a U-shaped change for the % T M A A^ -oxidation 
versus age occurred. Furthermore, no correlation was found between age and the 
percentage ofTMAiV-oxidation. This showed that the effect of age on the ability of 
T M A A^ -oxidation might not show any linear or logarithmic relationship. Since T M A 
is a substrate for flavin-containing monooxygenases (FMOs), especially for liver 
F M O , it is possible to extrapolate the data for human F M O activity. Therefore, the 
effect of age on the F M O activity might not show any linear or logarithmic 
relationship. The effects of age obtained in this study were similar to the results for 
many other enzyme studies in human and showed no special correlation for F M O 
activity with aging. Since only limited studies have been done before on the effect of 
age on F M O activity, other types of study, including the measurement of liver F M O 
activity and amount in liver biopsy samples, and longitudinal study to look at the 
change ofthe F M O activity assessed by T M A A^ -oxidation throughout the life-time of 
the volunteers, should be carried out. 
In the study of the effects of diet on T M A iV-oxidation, the four types of food were 
compared based on the percentage of T M A excreted as T M A O in urine at Periods 1 
and 4. It was clearly shown that intake of seafood (i.e. food rich in T M A , T M A O , or 
T M A precursors) but not the other types of food (beef, chicken, and others) increased 
the amounts of T M A and T M A O excreted, and it produced a higher percentage of 
T M A excreted as T M A O in urine. Moreover, the high T M A O amount and high rate 
of T M A O excreted in urine showed a significant positive correlation to the percentage 
value 0fTMA7V"0xidized. The correlation showed that high intake of T M A , T M A O , 
or T M A precursors could forther stimulate the liver F M O activity and as a result there 
was a higher T M A O excreted and higher percentage of TMAA^-oxidized. Moreover, 
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the above results were further confirmed by the results obtained from the five 
volunteers with controlled dietary intake, intake of seafood produced the highest 
percentage o f T M A excreted as T M A O in urine, and the highest amounts o f T M A and 
T M A O excreted. The effects were prolonged for several hours then the values 
dropped gently until most o f T M A and T M A O were excreted. 
In this study, patients with chronic liver disease showed impaired ability of T M A N-
oxidation {p < 0.001), while the other patient groups (hypertension, diabetes, 
hyperlipidaemia) appeared normal Q? > 0.05), when compared to normal volunteers. 
The lower percentage of T M A A^ -oxidized in patients with chronic liver disease was 
due to the severe liver damage, characterized by the elevated levels of bilirubin (65.8 
士 67.5 ^imol l_i) and alanine aminotransferase (ALT) (58.0 士 44.5 RJ 1"^ ) in these 
patients. The results clearly showed that the low percentage of T M A 7V-oxidation in 
these patients was caused by the impaired liver function. Although a previous study 
showed that diabetes might affect F M O activity, this study did not show any change 
in the percentage of T M A A^ -oxidation. Moreover, patients with hypertension who 
were treated with anti-hypertensive drugs and patients with hyperlipidaemia who were 
treated with statins also showed no effect on the T M A A^ -oxidation. These suggested 
that these types of drugs are unlikely to have a major effect on hepatic F M O activity 
because the liver function of these patients did not change on these treatments. Two 
drugs, atorvastatin and hydroxychloroquine also had no effect on the mean percentage 
of T M A excreted as T M A O in urine. However, three female patients treated with 
H C Q showed a reduced percentage ofTMAA^-oxidation (78 - 88 %). This raises the 
question why these three patients had a lower percentage value than other patients 
treated with H C Q . The changes might be caused by hormonal modulation but more 
clinical details are needed to assess these cases. 
Taken together, from the results obtained in this study, it can be concluded that about 
1 % ofthe Chinese population may have impaired ability of T M A A^ -oxidation (< 90 
% of T M A excreted as T M A O in urine). The result was similar to previous studies in 
British Caucasian populations. The percentage of T M A A/-oxidized was not affected 
by age, but intake of high-TMA foods (e.g. seafood) could increase the percentage 
value of T M A A^ -oxidation and the liver F M O activity in normal subjects. Therefore, 
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intake of seafood might be useful to characterize the presence of impaired ability of 
TMAA^-oxidation in man, due to the presence of large amounts of T M A and T M A O 
in seafood. Chronic liver disease lowered the percentage value of T M A 7V-oxidized 
due to the damage of liver and the reduction of liver function, while other diseases 
(diabetes, hypertension, and hyperlipidaemia) with normal liver function did not 
affect the percentage value of T M A A/-oxidation. Furthermore, atorvastatin and 
hydroxychloroquine also showed no apparent effect on the percentage of T M A N-
oxidation but other drugs should also be studied systematically. 
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Appendix A.1: Sample record sheet for food intake and activitv (English) 
Activity/Meal/Drink Record Sheet 
Name of Volunteer: Age: 
Address: 
Phone/Pager: 
Period ofRecord (From): (To): 
Are you smoker?# Yes No  
If 'Yes,, please indicate how many cigarettes you smoke per day:  
Important Notice: 
Please start to recordyour activities/meals/drinks from the dinnerjust before the experiment 
begins (12:00 a,nt, midnight). For example, ifyou have dinner at 8:00p,nt, 1st May, 1996， 
please start to recordyour activities/meals/drinks from 8:00 p.m., 1st May, 1996, but urine 
collecting activity is still begins from this midnight (12:00 a,m, 2nd May, 1996). 
Description of 
Date |^ 工騰 AM./PM. Activity Meals/Drinks/Medication Approx. Amount Taken* 
(hh:mm) Taken/Exercise Performed 
P.M. Dinner 
#please V the appropriate 




Date 丁血® A.M.fPM. Activity MealsA)rinksMedication Approx. Amount Taken* 
恤 讓 ） Taken/Exercise Performed 
*e.g. a cup oftea « 100 ml; a glass of water ~ 200 ml; a bowl of soup « 200 ml; a bowl of rice « 200 g 
Name of Analyst:  
Signature ofVolunteer: Signature of Analyst:  
Date: Date of Analysis:  
A-2 













曰 期 （ S n ) ^ / 活 動 （ 働 / 飮 料 ^ 勿 / 運 動 等 ） 大 繊 量 / 份 量 
下午. 晚飯 
#請在適當位置加上“號 
* - f m « 100毫升;一玻璃杯水« 200毫升；一碗湯« 200毫升；一碗飯« 200克 
( /P.2) 
A-3 
• tH 時間 上午/ 、法動 簡述 大約數量/份量 曰期 （hh:mm) 下午 估勤 （食物/飮料/藥物/運動等） 入彳」数 
* -iff^ « 100毫升;一玻璃杯水« 200毫升；一碗湯« 200毫升；一碗飯« 200克 
分析員姓名：  
參加者簽名： 分析員縛  
日期： 分析曰期：  
A-4 
Appendix B: Food intake and activity rernrd for volunteer A in COntrpl diet 
experiment 
Date Time (AMyTM) Activity Food Intake 一 Amount  
16/8/97~~8:00 PM Dinner Rice lBowl 
Shrimp 300 g 
Garoupa 190 g 
Broccoli LitUe bit 
Beer (Blue Ribbon) 355 ml 
Water 1 Glass 
^ : 4 5 PM Urination Sample 1 380 ml  
TO:OOPM Water ^ Glass  
17/8/97 l ^ : 1 5 A M Urination — Sample 2 190 ml  
T2 :30 AM Bedtime  
7:45 AM Wake up & Sample 3 600 ml 
Urination  
一 —Chinese Tea % Glass  
8:30 AM Breakfast Rice Roll ~ ~ 1 Dish (-200 g) 
Chinese Tea 1 Glass  
T0 :30 AM Urination Sample 4 350 ml  
一 —Chinese Tea 乂 Glass  
11:15 AM " c W e s e Tea % Glass  
T2:30 PM Urination Sample 5 380 ml  
12:45 PM Lunch Pork Steak 300 g 
Rice 1 Bowl 
Bitter Gourd Little Bit 
Cream Soda 355 ml 
Chinese Tea 么 Glass  
T : 0 0 PM — Urination Sample 6 360 ml  
— W a t e r 1/2 Glass  
~6:00 PM Urination Sample 7 360 ml  
7:00 PM Chinese Tea 1 Glass  
8:00 PM Urination Sample 8 l ^ Q ^  
8:30 PM Dinner Beef 600 g 
Rice /2 Bowl 
Beer (Blue Ribbon) 355 ml  
8:45 PM 一 Water 1/2 Glass  
l l : O O P M Urination Sample 9 360 ml  
11:10 PM Water V2 Glass  
l8/8/97l : lOAM Urination Sample 10 120 ml  
^ 1:15 AM — Water 1/2 Glass  
1:30 AM —— Bedtime  
8:30 AM Wake up & Sample 11 740 ml 
Urination  
8:50 AM Chinese Tea 1 Glass  
9:45 AM Breakfast Congee (w/ 70 g pork, some edible 3 Bowl 
flowers, ginger)  
10:00 AM — Chinese Tea /2 Glass  
11:15 AM Urination & Sample 12 560 ml 
Defeacation  
12:00 PM Chinese Tea 1/2 Glass  
~l ： 10 PM Urination Sample 13 160 ml  
1:15 PM Lunch Lettuce 7 5 g 
Apple 1 
Rice 1 Bowl  
Coke 355 ml  
B-1 
2:30 PM ChineseTea '/2Glass 
"^:00 PM Urination Sample 14 540 ml  
7:15 PM Soup (w/ tomato, chicken's liver, 2 Bowl 
kidney)  
T"55PM Urination — Sample 15 110 ml 
8:00 PM Dinner Chicken's Meat 150g 
Rice % Bowl 
Beer (Blue Ribbon) 355 ml  
l 0 : 4 5 P M Urination Sample 16 — 300 ml 
H : 3 0 P M — Water % Glass 
l l : 5 5 P M Urination 一 60 ml 
19/9/97 l2:OOAM — Bedtime — 
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